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Zusammenfassung 
In gesunden Menschen führt eine Infektion mit dem humanen Cytomegalievirus (HCMV), wenn 
überhaupt, lediglich zu milden Symptomen. Jedoch stellt die anschließende lebenslange Latenz, 
Neuinfektionen oder die Reaktivierung aus der Latenz in immunsupprimierten Individuen ein 
schwerwiegendes Problem für das öffentliche Gesundheitswesen dar. Besonders betroffen sind dabei 
AIDS- und Transplantat-Patienten, sowie der sich entwickelnde Fötus, in denen ein Ausbruch einer 
CMV-Infektion zu einem lebensbedrohlichen Krankheitsbild führen kann. Da derzeit noch kein 
Impfstoff zur Verfügung steht, werden CMV-Infektionen medikamentös behandelt. Alle auf dem Markt 
befindlichen CMV-Medikamente sind gegen die virale Polymerase gerichtet und bringen das Problem 
der Langzeittoxizität und auftretender Resistenz mit sich. Aus diesen Gründen besteht großes 
Interesse an neuen anti-CMV Medikamenten, die gegen andere virale Zielstrukturen gerichtet sind. 
Essentielle virale Protein-Protein Interaktionen könnten solche potentiellen Targets darstellen.  
 
Im Rahmen dieser Arbeit wurde ein Hochdurchsatzscreen etabliert, um Inhibitoren für die Interaktion 
zwischen den HCMV Proteinen pUL50 und pUL53 zu finden. Die Proteine interagieren direkt 
miteinander und sind Bestandteil eines Komplexes, der für den Kernaustritt des viralen Capsids 
essentiell ist. Der Hochdurchsatzscreen basierte dabei auf der Technik des Proteinfragment 
Complementations Assays (PCA), in dem zwei inaktive Proteinteile eines Reporterenzyms, in diesem 
Fall der N- und C-terminale Teil der TEM-1 β-lactamase von E.coli, an die entsprechenden 
interagierenden Proteine fusioniert werden. Die Interaktion der Proteine führt zur räumlichen Nähe der 
Reporterfragmente, die zur Faltung und Rekonstitution der Aktivität führt. Im Falle der Anwesenheit 
eines Inhibitors dieser Interaktion wird die aktive Form nicht oder nur vermindert gebildet. Um 
möglichst viele potentielle Inhibitoren kostengünstig und ohne Rücksicht auf zelltoxische Nebeneffekte 
testen zu können, wurden die Fusionsproteine in E.coli exprimiert, aufgereinigt und im Test von 4,000 
chemischen Verbindungen kombiniert. Dabei wurden zwei strukturell verwandte Leitsubstanzen als 
direkte Inhibitoren der Interaktion von pUL50/pUL53 in vitro identifiziert.  
 
Zusätzlich wurde ein weiterer spezifischer PCA, der die Interaktion der essentiellen HCMV Proteine 
pUL94/pUL99 im PCA System darstellt etabliert, um in späteren Hochdurchsatzscreens einen 
spezifischen Inhibitor für die sekundäre Umhüllung von HCMV identifizieren zu können.  
 
Zusammenfassend berichtet die vorliegende Arbeit über die Etablierung eines neuen in vitro 
Proteinfragment Complementations Assays welcher sich als schnell, extrem spezifisch und deshalb 
geeignet für Hochdurchsatzscreens zeigte. Dieser Assay ist generell anwendbar und resultierte bereits 
in der Identifizierung einer Leitstruktur für die Inhibition des Kernaustrittskomplexes von HCMV. 
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Summary 
Infection of healthy individuals with human cytomegalovirus (HCMV) is only associated with 
mild symptoms. However, the subsequently established life-long latency, primary infections 
or reactivation from latency in immunocompromised individuals demonstrate a severe public 
health problem. In particular, in patients with AIDS and transplant recipients as well as in the 
developing foetus, HCMV infections can cause fatal disease. Since there is still no vaccine 
available, human CMV infections are controlled by antiviral therapy. All currently licensed 
anti-CMV drugs target the viral polymerase and are accompanied by problems like long-time 
toxicity and the occurrence of resistance. Therefore, there is a major interest in new anti-
CMV drugs affecting other viral targets. Essential viral protein-protein interactions could 
demonstrate such potential drug targets.  
 
In this work, a high-throughput screen was established to identify inhibitors for the interaction 
of the HCMV proteins pUL50 and pUL53. The proteins directly bind to each other and are 
part of a complex which is crucial for the process of nuclear capsid egress. The high-
throughput screen was thereby based on the technique of protein fragment complementation 
assay (PCA) in which two inactive fragments of a reporter protein, in this case the N- and C-
terminal part of TEM-1 β-lactamase of E.coli, are fused to the corresponding interacting 
proteins. Interaction of the proteins leads to proximity of the reporter fragments, followed by 
proper folding and reconstitution of the reporter activity. In case of the presence of an 
inhibitor of the protein interaction the active reporter is not reconstituted or formed to a lower 
amount. In order to test many potential inhibitors in a cost effective way and regardless to 
cytotoxic side effects the fusion proteins were expressed in E.coli, purified and combined in a 
screen of 4,000 chemical compounds. Thereby, two structurally related lead compounds 
were identified as direct inhibitors of the pUL50/pUL53 interaction in vitro.  
 
In addition, a further specific PCA monitoring the interaction of the essential HCMV proteins 
pUL94/pUL99 was established aiming a future high-throughput screening to identify specific 
inhibitors of the secondary envelopment of HCMV. 
 
Collectively, the presented work reports about the establishment of a novel in vitro protein 
fragment complementation assay which appeared to be fast, extremely specific and therefore 
suitable for HTS. This assay is generally applicable and already resulted in identification of a 
lead structure for inhibition of the nuclear egress complex of HCMV. 
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1. Introduction 
1.1 The family of herpesviridae 
The family of herpesviridae (gr. herpein = creep) was initially classified by the unique 
architecture of the virion (see 1.1.1). To date, based on this morphological taxonomy, more 
than 200 herpesviruses have been identified in vertebrates including several human 
pathogens. The common feature of all herpesviruses is that in lytic infection their capsids 
assemble in the nucleus, whereas maturation and formation of infectious progeny takes 
place in the cytoplasm. Another general characteristic for all herpesviruses is the ability to 
establish a life long latency in the host. During latency no infectious viral particle can be 
detected. In the cells harbouring latent virus, viral genomes are maintained in a circular form 
and only a minimal viral gene expression takes place ensuring genome persistence. 
On the basis of biological criteria such as host range, length of replication cycle and cell 
tropism, herpesviruses are classified into α-, β- and γ-herpesvirus subfamilies. 
α-herpesviruses, with the most prominent members Herpes Simplex Virus 1 (HSV-1), HSV-2 
and Varicella-Zoster Virus (VZV), are characterized by a broad host range and a short 
replication cycle with sensory ganglia as main target of infection. In contrast, long 
reproductive cycle, a broad cell tropism but strict species specificity qualifies the subfamily of 
β-herpesviruses including the genera of cytomegaloviruses (HCMV), muromegalovirus 
(MCMV) as well as the human herpesvirus 6 and human herpesvirus 7. γ-herpesviruses, 
where Kaposi-sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are the 
human representatives, infect preferentially cells of the lymphatic system, like T- and B-cells. 
However, the duration of their replication cycle varies drastically between species. 
 
1.1.1 Virion structure 
In general, a herpes virion contains a linear double-stranded DNA core in an icosahedral 
capsid, enveloped by an amorphous-appearing proteinaceous material called tegument 
layer, which is enclosed by a lipid bilayer embedding several viral glycoproteins (Figure 1). 
Mature herpesvirus particles (virions) vary in size from 120 to 260 nm depending on the 
thickness of their tegument and the state of the envelope.  
The mature HCMV virion is 150-200 nm in diameter, and composed of a 100 nm large 
icosahedral capsid that is filled with a linear 230 kbp double-stranded DNA genome coding 
for approximately 200 genes (Streblow, 2006). Besides viral structural proteins, the tegument 
harbours viral and cellular mRNAs which can be translated immediately upon virus entry 
(Bresnahan and Shenk, 2000). A lytic HCMV infection produces three types of viral particles: 
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Infectious particles, non-infectious enveloped particles (NIEPs), which contain a capsid but 
no genome, and dense bodies (DBs), which are enveloped but lacking capsid and genome. 
 
 
 
Figure 1: Virion structure of herpesviruses. (A) Schematic representation of a herpesvirus particle 
consisting of an icosahedral capsid encasing the viral genome, the surrounding tegument layer which 
is enveloped by the viral membrane in which different glycoproteins are embedded (Copyright Marko 
Reschke, University of Marburg). (B) Herpesviral particle detected by electron microscopy (Klupp et 
al., 2004). 
 
1.1.2 Herpes virus replication cycle 
Herpesvirus infection of a host cell starts by interaction of glycoproteins embedded in the 
viral envelope with receptors on the cellular surface (Spear and Longnecker, 2003). Entry 
then occurs by fusion of the plasma membrane with the virion envelope by an unknown 
mechanism and tegument constituents and the capsid are released into the cytoplasm 
(Figure 2). The capsid is transported along microtubules to the nuclear pores (Sodeik, 
Ebersold, and Helenius, 1997) where it docks and releases the viral DNA into the nucleus. 
Transcription of the viral genome occurs in consecutive phases resulting in immediate-early, 
early and late mRNAs. The latter mainly code for structural components like capsid- and 
tegument-constituents, which are translated in the cytoplasm and some are transported to 
the nucleus where the first part of the assembly process takes place. The viral genome 
replication leads to concatomeric DNA, which is cleaved into unit-length genomes upon 
packaging into the pre-formed capsids. These mature nuclear capsids (nucleocapsids) then 
need to be transported to the cytosol. In an early step of this transport process, called 
nuclear egress, the nucleocaspids bud at the inner nuclear membrane to get into the 
perinuclear space, thereby acquiring an envelope derived from the inner leaflet of the nuclear 
membrane. In a following step the primary envelope fuses with the outer leaflet of the nuclear 
membrane, resulting in loss of the primary envelope. In all herpesviruses the nuclear egress 
is governed by two viral proteins belonging to the UL31 and the UL34 family (see 1.3.2.1). 
Naked capsids translocate into the cytoplasm, where they acquire their final tegument. 
Tegumented virus particles are assumed to be targeted to vesicles of the Golgi-apparatus 
A B 
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where they are finally enveloped (Sanchez et al., 2000). It is still unclear how tegumented 
particles reach the site of secondary envelopment and how viral glycoprotein assembly takes 
place, however it is suggested that proteins belonging to the UL11 and the UL16 family as 
well as their specific interaction are involved (chapter 1.3.1.2). Re-enveloped particles are 
retained in the vesicles and transported via the secretory pathway, where they fuse with the 
plasma membrane to release the virus particle into the extracellular compartment. 
 
 
 
1.2 Human cytomegalovirus (HCMV) 
Cytomegalovirus is an ubiquitous human β-herpesvirus, its systematic name is human 
herpesvirus type 5. Its common name was proposed by Weller in 1957 (Craig et al., 1957) to 
reflect both virus-induced cytopathic effects (syncytia formation resulting in large, 
multinucleated cells) and the role of the virus in congenitally acquired cytomegalic inclusion 
disease. HCMV can be found in 40% to 90% of human populations worldwide and is the 
most prevalent congenital transmitted virus. β-herpesviruses show high species specificity. 
Hence, human herpesviruses belonging to this subfamily are not suitable for studying the 
entire spectrum of their infection biology. Therefore closely related viruses of mice and 
guinea pigs and monkeys serve as animal model. Murine cytomegalovirus (MCMV) is the 
best studied animal model for HCMV showing significant similarities in their biology and 
Figure 2: Replication cycle of 
herpeviruses 
The virion absorbs via viral glycoproteins 
at special receptors on the cell surface. 
Fusion of the viral and cellular membrane 
is initiated and the viral capsid (red 
hexagons) is released into the cytoplasm 
and transported to the nuclear pores. 
The viral genome is released into the 
nucleus where it circularizes. 
Three classes of viral genes (immediate-
early, early and late) are transcribed 
chronologically and translated into 
proteins. Late proteins (blue) assemble to 
capsids, which incorporate newly 
synthesized viral DNA. DNA-filled 
capsids (nucleocapsids) leave the 
nucleus by budding at the inner nuclear 
membrane in the perinuclear space. 
Primary envelopment is lost by fusion 
with the outer nuclear membrane and 
capsids are released into the cytoplasm 
where final envelopment occurs by 
budding into special vesicles. The virion 
is released by exocytosis (Coen and 
Schaffer, 2003). 
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pathogenesis of infection, subsequent disease development and the establishment of latency 
(Brune, 2011; Hudson, 1979; Reddehase, Podlech, and Grzimek, 2002). 
 
1.2.1 Clinical relevance 
In immunocompetent individuals primary infection with HCMV is mostly asymptomatic 
resulting in a lifelong latent infection of the host. Reactivation of latency under certain 
conditions can be observed with or without clinical symptoms.  
In contrast, HCMV is a highly relevant pathogen in individuals with innate, acquired or 
therapeutically induced immune deficiencies. In connately infected children who acquired the 
infection from their mother primary infected during pregnancy, HCMV induces cytomegalic 
inclusion disease. There is a remarkable variation between the phenotype of the resulting 
HCMV disease between the different patient groups, depending on the type of their 
underlying disease and the strength of the immunosuppression. In AIDS patients HCMV 
disease leads to retinitis and gastrointestinal ulcers (Jacobson et al., 1988), whereas in bone 
marrow/stem cell transplant or solid organ transplant patients it can result in pneumonitis, 
enteritis and viremia (Fishman and Rubin, 1998; Miller et al., 1986; Rubin, 2001). Around 
2.5% of all newborns are infected with HCMV and 10% of infected children are already 
affected at birth, further 10% to 15% develop the symptoms later including severe 
neurological defects affecting the auditory system and/ or mental retardation (Harris et al., 
1984; Neuberger et al., 2006; Ornoy and Diav-Citrin, 2006; Raynor, 1993; Rivera et al., 
2002). In newborns, congenital CMV infection is the most common cause of non-hereditary 
hearing loss (Morton and Nance, 2006). 
 
1.2.1.1 Vaccines 
The major driving force behind the efforts to develop a HCMV vaccine is definitively the 
problem of the congenital HCMV infection. Although antiviral therapy in newborns with 
neurologic involvement shows some benefit in prevention of hearing deteriorations (Kimberlin 
et al., 2003), the success of the therapy is limited and the toxicity of available antiviral drugs 
are of concern. The economic costs of the society in caring for neurodevelopmental disability 
of children caused by congenital HCMV infection are a compelling argument for the Institute 
of Medicine to assign a vaccine to prevent CMV the highest priority (Stratton, 2001). Efforts 
were made over more than thirty years; however, no HCMV vaccine appears to be 
approaching imminent licensure up-to-date. The adaptive immune response, including 
humoral and T-cell mediated effector mechanisms, plays an important role in establishment 
of a long-lasting immunity, which serves to control HCMV reactivation and serious HCMV 
disease (Crough and Khanna, 2009). Trials with live, attenuated HCMV vaccines like the 
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laboratory-adapted clinical isolate, the Towne strain, resulted in neutralizing antibodies, as 
well as CD4+ and CD8+ T lymphocyte responses, which provided some protective impact on 
HCMV disease (Plotkin et al., 1994). However, a protection against infection, disease or 
reactivation was not assured. This was assumed to be caused by an over-attenuation 
resulting in an inadequate immune response following vaccination (Jacobson et al., 2006). 
Yet, the molecular basis of this apparent attenuation is still unclear. There are attempts going 
on in improvement of the immunogenicity of the Towne strain, but the concerns about 
potential risks of establishing a latent or persistent HCMV infection hindered the progress of 
live-attenuated vaccine studies. This stimulated the development of other vaccination 
strategies such as subunit or DNA vaccines. However, the HCMV vaccine development field 
still suffers from the lack of clarity specifying which HCMV features are indispensable and 
have to be included in the vaccine to result in a protective immunity (Schleiss, 2008). 
 
1.2.1.2 Antiviral therapy of HCMV 
Due to the lack of a vaccine, antiviral drugs for the treatment of HCMV infection and disease 
are of great importance but there are only a limited number of drugs which are licensed to 
date (reviewed in (Lischka and Zimmermann, 2008)). Still the designated gold standard is the 
nucleoside analog Ganciclovir (GCV) or its oral prodrug Valganciclovir (VGCV) (both Figure 
3), respectively, which are selectively monophosphorylated by the viral kinase pUL97. 
Subsequently, they are converted by cellular kinases to triphosphate which targets the viral 
DNA polymerase. Its incorporation into the newly synthesized viral DNA strand leads to 
strand breaks and to substantial slow down of viral DNA synthesis. The same mode of action 
shows the broad-spectrum antiviral cidofovir (Figure 3) with the exception, that no initial 
phosphorylation step is required. Foscarnet (Figure 3) is a further HCMV drug targeting the 
DNA polymerase. It is a pyrophosphonate analog that directly binds to the pyrophosphonate 
binding site of the viral polymerase, thus preventing cleavage of the terminal pyrophosphate 
group of the growing DNA strain by product inhibition.  
Although Acyclovir (not shown) or its oral prodrug Valacyclovir (VACV, Figure 3) have 
primarily been developed for the suppression of Herpes Simplex Virus (HSV), prophylactic 
use of VACV also showed the potency to reduce the incidence of HCMV disease (Lowance 
et al., 1999). Their mechanism of action is similar to GCV, however, it is a less efficient 
substrate for pUL97 than for HSV thymidine kinase. Therefore, VACV lacks sufficient 
potency to be used for the treatment of active infection and has only been approved for 
prophylaxis.  
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Fomivirsen (FOM) (not shown) is an antisense drug with a 21-nucleotide sequence 
complementary to the immediate early region 2 of CMV messenger ribonucleic acid. It is 
locally used in AIDS patients to treat cytomegalovirus retinitis. 
The currently available drugs have considerable helped in the management of HCMV 
disease in immunocompromised patients. However, their use is limited due to toxicity, poor 
oral bioavailability, modest efficacy, and development of virus-drug resistance. Especially in 
the case of drug resistance, the drugs suffer from the fact that all except fomivirsen target the 
DNA polymerase, leading to cross-resistance, resulting in an urgent need of new drug 
targets. 
 
Figure 3: Chemical structures of approved anti-HCMV drugs. (Lischka and Zimmermann, 2008). 
 
1.2.1.3 Current strategies in anti-HCMV drug development 
There are several potential targets for pharmaceutical inhibition in the viral replication cycle, 
as virus attachment and entry, viral gene expression and DNA replication or in the steps of 
virus assembly and egress. 
In a recent investigation for HCMV specific drugs (Melnik, Garry, and Morris, 2011) 
therapeutic peptides were studied targeting glycoprotein B (gB). gB is a highly conserved 
essential HCMV protein, that specifically promotes fusion of the viral envelope with the host 
cell. It was already shown in previous studies that synthetic peptides corresponding to or 
overlapping with these regions in viral fusion proteins sometimes serve as viral entry 
inhibitors (Akkarawongsa et al., 2009; Lambert et al., 1996; Sainz et al., 2006). These 
peptides have potential in the treatment of pregnant women as they show no statically 
significant toxicity. 
Artesunate (ART), a semi-synthetic derivative of the natural product artemisinin, applies as a 
promising candidate in treatment of HCMV infections. It is in use in treating of severe malaria 
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(Adjuik et al., 2004; Gomes et al., 2008), but its antiviral activity against HCMV in vivo and in 
vitro could also be shown (Efferth et al., 2002; Kaptein et al., 2006). Though the antiviral 
mode of action of ART is not yet completely elucidated, the mechanism of inhibition seems to 
be unique as it interferes with HCMV at the very early stage of viral replication (Chou et al., 
2011) likely by inhibition of pro-viral cell signalling process (Efferth et al., 2002; Efferth et al., 
2008). 
Recent targeted approaches for anti-HCMV drug development mainly concentrated on two 
promising novel drug targets: the viral terminase complex and the viral protein kinase pUL97. 
The terminase is a two-subunit enzyme that catalyzes cleavage and packaging of viral DNA 
(Bogner, 2002). Several different substances targeting this enzyme were discovered (e.g. 
BDRCRB, GW275175X, and BAY38-4766, AIC246) but due their inactivation in vivo, most of 
them did not reach phase II clinical trials (Lischka and Zimmermann, 2008). Only the 3,4-
dihydro-quinazoline-4-yl-acetic acid derivative AIC246, which was shown to target the pUL56 
subunit of the terminase (Goldner et al., 2011), was undergoing phase II evaluations and 
now enters clinical phase III. 
Maribavir is a benimidazole-ribonucleoside derivative which targets the viral serine/threonine 
kinase pUL97, an enzyme that is involved in viral DNA synthesis and nuclear egress. 
Resistant strains also showed mutations in the UL27 gene, encoding a protein of unknown 
function. It was a very promising candidate with a favourable clinical safety profile and 
already entered phase III clinical trials. Since maribavir failed in a decisive phase III clinical 
trials, it is uncertain, if this drug will ever be licensed (ViroPharma, 2009a; ViroPharma, 
2009b). 
 
1.3 Approaches in drug development 
In general, there are two different strategies in the process of drug discovery/development. 
The first, called rational drug design, requires the knowledge of the structure of either the 
basic molecule of a specific inhibitor (ligand based drug design) or of the three dimensional 
structure of the biological target (structure assisted drug design), which is obtained through 
methods such as x-ray crystallography or NMR. Most of the currently available anti-HCMV 
drugs mentioned in the previous chapter resulted from the ligand based approach, because 
their structures descend from the polymerase substrate. One example for structure-assisted 
drug design in the field of virology is the design of SARS-protease inhibitors. After the 
prediction of the structure by homology modelling (Anand et al., 2003) there was effort put 
into the design of inhibitory compounds (Yang et al., 2005). Rational drug design is a very 
hypothesis driven approach and once a compound is claimed in silico, it needs experimental 
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validation. Hit rates are expected to be low, but once it identifies a candidate it can be very 
effective to drastically shorten the discovery and optimisation process. 
The other strategy in the process of drug discovery is high-throughput screening (HTS), 
wherein large libraries of chemicals are tested for their ability to inhibit a specific target 
(target-based) or variegate a distinct phenotype (phenotype-based). Whereas in the 
phenotype-based approach the substances are applied and analyzed in the context of living 
cells or tissue, in the target-based approach the effect of the test substances on the defined 
molecular target is investigated directly. Enzymes, protein-protein interactions or protein-
DNA interactions can serve as defined biochemical targets. The effect of the substances on 
the target is displayed in HTS by assays like binding, enzyme activity or yeast two-hybrid 
(Y2H) based assays. For readout mostly biochemical methods can be applied, where a 
signal is measured as change in colour intensity, fluorescence or luminescence signal.  
 
1.3.1 Protein-protein interactions as potential drug targets 
Sustained investigations into protein-protein interactions have revealed their key role in 
regulating a wide range of cellular processes. Not surprisingly, many human diseases can be 
traced to abnormal protein-protein interactions involving endogenous proteins, proteins from 
pathogens or both (Ryan and Matthews, 2005). A variety of different approaches has been 
used to inhibit specific protein-protein interactions with the goal of developing therapies for 
different human diseases. Antibodies that block protein-protein interactions or sequester 
different members of a protein complex represent a strategy, because they tend to bind their 
target with high specificity and affinity. However, due to their large size, antibodies are not 
well suited to intracellular targets. Oligo-peptide inhibitors are a much smaller alternative, 
which can be very successful interfering with protein-protein interaction, though they suffer 
from instability in vivo. Therefore, the prospect of using small molecules to block interactions 
is attractive circumventing these pharmacological problems; however, this was also viewed 
with much scepticism considering biochemical aspects. It was expected that it would be 
difficult to specifically target interaction sites by a small molecule, which can be large and 
quite hydrophobic. However, progress in small molecule design and screening made this 
approach far more feasible (Pagliaro et al., 2004; Zhao and Chmielewski, 2005).  
A prerequisite for the development of therapeutics against protein-protein interactions in 
disease is the basic understanding of complex formation by the targeted proteins. Knowledge 
about interaction partners or sites give are more detailed view on the comprehensive picture 
facilitating the decision for the later target and strategy of therapeutic development.  
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1.3.2 Essential intraviral protein interactions of HCMV as potential drug-targets 
HCMV is the largest of the human herpesviruses composed of a 230 kbp DNA genome with 
a predicted coding capacity from 160 to more than 200 open reading frames (Murphy et al., 
2003a; Murphy et al., 2003b). Cytomegalovirus genes can be grouped into two broad 
categories; those essential for replication in cell culture (core genes) and those dispensible 
for virus replication. BAC mutagenesis studies indicated 45 ORFs essential for viral 
replication in fibroblasts (Dunn et al., 2003). The infectious viral particle was shown to 
comprise of as many as 71 proteins (Varnum et al., 2004). Much of what is currently known 
about the intraviral protein-protein interactions of HCMV has been investigated by yeast-two 
hybrid analysis (Fossum et al., 2009; Phillips and Bresnahan, 2011b; To et al., 2011; Wood 
et al., 1997). Furthermore, a set of core interactions could be identified conserved throughout 
all herpesvirus subfamilies (Fossum et al., 2009; and see next chapters). 
 
1.3.2.1 The pUL50/pUL53 interaction in the process of nuclear egress 
The nuclear envelope of eukaryotic cells is composed of a double lipid-bilayer, the 
embedded nuclear pore complexes and an underlying nuclear lamina network. After 
assembly, nucleocapsids have to overcome the physical barrier of nuclear membranes and 
lamina because their size with around 120 nm exceeds the tolerated magnitude of transport 
machinery associated to the nuclear pore complexes (~39 nm) (Pante and Kann, 2002), 
generally mediating the transport between nucleus and cytoplasm. Therefore, herpesviruses 
developed a special mechanism for the nuclear capsid export akin to that which was recently 
elucidated for large RNP granules during synaptic Wnt signalling (Speese et al., 2012). In the 
first step of nuclear egress, capsids bud at the inner nuclear membrane into the perinuclear 
space by acquiring an envelope (Darlington and Moss, 1968). In this process two viral 
proteins that form a complex at the nuclear envelope, referred to as the nuclear egress 
complex (NEC), have been shown to be crucial (Figure 4A). Throughout the alpha, beta, and 
gamma herpesviruses, highly conserved homologs of these two proteins are found to form 
an NEC at the nuclear rim in all studied cases (Bubeck et al., 2004; Fuchs et al., 2002; 
Gonnella et al., 2005; Lake and Hutt-Fletcher, 2004; Lotzerich, Ruzsics, and Koszinowski, 
2006; Reynolds et al., 2001; Yamauchi et al., 2001) and are assigned to the pUL34 and 
pUL31 herpesviral protein families. The corresponding representatives of these two proteins 
in HCMV are called pUL50 and pUL53 and have been categorized as essential for virus 
replication (Dunn et al., 2003; Yu, Silva, and Shenk, 2003). pUL50 and its homologs in the 
pUL34 protein family are type II C-terminally anchored membrane proteins, which reside 
primarily at the nuclear envelope (Shiba et al., 2000) and are expressed in the early to late 
phase of infection. Proteins of the pUL31 family, including pUL53, are expressed late in 
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infection and harbour an N-terminal nuclear localization signal (Lotzerich, Ruzsics, and 
Koszinowski, 2006). In absence of its partner pUL53 is localized in the nucleosol but upon 
co-expression of pUL50, pUL53 is recruited to the nuclear rim (Dal Monte et al., 2002). It was 
shown that pUL50 directly interacts with pUL53 (Milbradt, Auerochs, and Marschall, 2007; 
Sam et al., 2009) as it is also observed for their homologous proteins in MCMV, HSV, PrV 
and Epstein-Barr virus (Bubeck et al., 2004; Fuchs et al., 2002; Gonnella et al., 2005; Lake 
and Hutt-Fletcher, 2004; Lotzerich, Ruzsics, and Koszinowski, 2006; Reynolds et al., 2001; 
Yamauchi et al., 2001). Binding sites of heterodimerization were predicted as small linear 
motifs in the proteins (Figure 4B) (Lotzerich, Ruzsics, and Koszinowski, 2006; Sam et al., 
2009). The complex is supposed to be involved in lamina destabilization (Reynolds, Liang, 
and Baines, 2004). Remarkably, in cells stably co-expressing the pUL31 and pUL34 of PrV, 
the NEC is capable of remodelling the nuclear membrane to form vesicles resembling the 
primary enveloped particles during infection in absence of any other viral protein (Klupp et 
al., 2007). It is postulated that lamina distortion is dependant on the phosphorylation of 
nuclear lamins (Lotzerich, Ruzsics, and Koszinowski, 2006; Muranyi et al., 2002; Sanchez 
and Spector, 2002). A recruitment of kinases is ascribed to pUL50 and pUL53 during the 
process of nuclear egress. In particular, it was shown that pUL50 and also its MCMV 
homolog pM50 is interacting with the cellular protein kinase C and re-localizes it to the 
nuclear lamina (Milbradt, Auerochs, and Marschall, 2007; Muranyi et al., 2002). Furthermore, 
pUL50 interacts with the cellular protein p32, a multifunctional lamina constituent, which itself 
binds to the viral protein kinase pUL97 (Marschall et al., 2005). Thus, the pUL50/pUL53 
complex is supposed to serve as a docking station for cellular and viral proteins in order to 
disrupt the nuclear lamina meshwork. Members of the pUL31 protein family seems to have 
also another function in an upstream step of capsid maturation and packaging of viral DNA 
as it was described for MCMV pM53 functions, but which is independent from the interaction 
with the pM50 (Popa et al., 2010) (Pogoda et al., 2012, in revision). 
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Figure 4: The HCMV pUL50 and pUL53 proteins. (A) Model of the nuclear egress process of viral 
capsids. HCMV capsids assemble and are packed with viral DNA in the nucleus (C). pUL50 and 
pUL53 interact at the inner nuclear membrane (1) and act as docking station for nuclear capsids (2) 
with tegument proteins (triangles) as adapter proteins. This configuration forms the nuclear egress 
complex (NEC) (3). The capsids bud at the nuclear membrane (4) before they are released into the 
cytoplasm (5) (Figure kindly provided by Margit Schnee). (B) Schematic representation of pUL50 and 
pUL53 of HCMV. pUL50 contains an N-terminal conserved region (CR) and a predicted 
transmembrane helix near to its C-terminus (TM) separated by a variable region (VR). pUL53 consists 
of four conserved regions (CR1-4). The predicted binding sites are located near to the N-termini of 
both proteins (open black and grey boxes). 
 
1.3.2.2. The pUL94/pUL99 (pp28) interaction in the process of secondary envelopment 
After fusion with the outer leaflet of the nuclear membrane viral particles loose their primary 
envelope and enter the cytoplasm as naked capsids. A complex network of protein-protein 
interactions is responsible to aid acquisition of the final tegument proteins and the final 
(secondary) envelope. However, due to intricacy and redundancy between different 
herpesvirus systems, the mechanism of the tegumentation and the secondary envelopment 
is still not completely elucidated. As the result of the final step of secondary envelopment of 
tegumented viral particles the infectious particles are formed by budding into Golgi-derived 
vesicles.  
The highly abundant pUL99 (pp28) tegument protein (Baldick and Shenk, 1996; Landini et 
al., 1987; Martinez and St Jeor, 1986), which is encoded by the UL99 ORF of HCMV 
(belonging to the conserved UL11 protein family of herpesviruses), is a 190-aa myristoylated 
aa 1-397
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phosphoprotein (Chee et al., 1990), which was shown to be expressed in virus replication 
with early-late kinetics (Jones and Lee, 2004). During infection, it accumulates on 
cytoplasmatic faces of nuclear and Golgi apparatus-derived membranes (Homman-Loudiyi et 
al., 2003; Sanchez et al., 2000). In further studies it was shown to play a crucial role in the 
process of final envelopment (Britt et al., 2004; Silva et al., 2003); pUL99-deficient HCMV 
mutants were not able to produce infectious virus and were shown to generate cytoplasmic, 
DNA-containing, tegument-associated capsids, but the capsids failed to acquire an envelope. 
pUL99 was shown to interact with tegument protein pUL94 (Liu et al., 2009), a member of 
the conserved pUL16 protein family of herpesviruses. This interaction can also be found for 
the MCMV homologs pM99 and pM94 (Maninger et al., 2011) as well as for their α-
herpesvirus homologs pUL11 and pUL16 (Loomis et al., 2001; Yeh, Meckes, and Wills, 
2008). Recently, Phillips and Bresnahan (Phillips and Bresnahan, 2011a) demonstrated that 
pUL99 is essential for HCMV and confirmed its crucial role in secondary. The same was 
shown for the MCMV homolog pM94 (Maninger et al., 2011). Null phenotypes of pUL94 or 
pM94 showed a defect in secondary envelopment without influence on any preceding viral 
replication steps. Furthermore, the null-phenotype of pUL94 exhibited aberrant localization of 
the interaction partner pUL99. This suggested a directing function of pUL94 for pUL99 to the 
site of secondary envelopment (Meckes, Marsh, and Wills, 2010; Phillips and Bresnahan, 
2011a). This notion was recently accredited by the observation that a failure in the 
pUL94/pUL99 interaction lead to abberant localization of both proteins and a complete block 
in production of infectious virus (Phillips et al., 2012). 
Moreover, pUL94 and its homologs have nuclear and cytoplasmic localization and are tightly 
virion associated (Meckes, Marsh, and Wills, 2010). This leads to the hypothesis, that pUL94 
connects the capsid with the Golgi-derived vesicles by interaction with Golgi-network 
associated pUL99 to enable secondary envelopment (Figure 5). 
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Figure 5: Model for the role of pUL94 and pUL99 in the secondary envelopment process. pUL94 
interacts with pUL99 (1) (membrane association not shown) and directs pUL99 to trans-Golgi derived 
vesicles harbouring several viral tegument and glycoproteins (black) (2). pUL94 acts as a linking 
protein by interacting with the naked, pre-tegumented capsids. This configuration forms the secondary 
envelopment complex (SEC) (3). The capsid gets enveloped by budding into the vesicles (4). The 
vesicles are transported to the cytoplasmic membrane (5) where virions are released upon fusion (6) 
(Figure modified from (Mettenleiter, 2004)). 
 
Amino acids 22-43 of pUL99 were identified as being responsible for its binding with pUL94, 
while no linear motif could be found within pUL94 (Liu et al., 2009). However, in the MCMV 
homolog pM94 a dominant-negative mutant with a small 5 aa insertion in the N-terminus of 
the protein was described not to form a detectable complex with pM99  (Maninger et al., 
2011). Furthermore, a pUL94 mutant was recently described harbouring a point mutation in 
the C-terminus of the protein which totally lost co-localization to pUL99 (Liu et al., 2012). Due 
to these observations, there is evidence that a small molecule inhibitor targeting this 
interaction can be found which acts as an antiviral against HCMV in blocking secondary 
envelopment. 
 
1.4 Monitoring protein-protein interactions 
Classical methods as co-immunoprecipitation and pull down assays, still apply as the gold 
standard for detection of protein-protein interactions. Both methods are based on affinity 
purification of the bait protein, which binds to a matrix directly or via an additional tag. Protein 
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complexes in which the bait protein is part of are specifically retained by the matrix and can 
be co-purified with the bait. In case of the co-immunoprecipitation assay an antibody against 
the bait protein replaces the function of a tag. However, both methods are robust and reliable 
they are not useful for high-throughput screens. A very popular method to monitor and reveal 
protein-protein interactions for larger scale approaches is the yeast-two hybrid (Y2H) system 
(Fields and Song, 1989). Low costs, easy handling and in vivo-like conditions (e.g. post-
translational modifications in yeast) made Y2H a tool for large screen set-ups of interacting 
proteins, so called interactomes. Recently, a study on evolutionary conserved herpesviral 
protein interaction networks was published based on the Y2H system (Fossum et al., 2009). 
Beside of its many advantages, Y2H suffers from limitations; for example that it is limited to 
soluble proteins. Furthermore the protein-protein interaction has to take place in the nucleus 
which is for some proteins not the compartment they originally occur and act. This could lead 
to abnormal folding and binding properties of the proteins which could influence the result of 
the screen. Improper folding could also result from aberrant post-translational modifications 
occurring in yeast which differ from other eukaryotes and the incompatibility of the fusion with 
the reporter fragment. Therefore, results from Y2H screens always need to be validated by 
other methods like co-immunoprecipitations and pull-down assays.  
 
1.4.1 Protein fragment complementation assay 
Based on the principle of Y2H with the split reporter parts a new method, the so called 
protein fragment complementation assay (PCA), evolved over the last two decades 
overcoming the certain disadvantages of the original method (see previous chapter).  
In the PCA, a protein-protein interaction is measured by fusing each of the proteins partners 
to complementary fragments of a reporter enzyme that has been dissected into two 
fragments. The PCA-fragments are designed so that they are non-functional by themselves 
and cannot bind to each other by their own. The PCA-fragments are brought into proximity 
through association of the two fused interacting proteins, which aid the folding and 
reconstitution of the active reporter from the two spited fragments. Depending on the used 
reporter (enzymes, GFP, luciferase, antibiotic resistance markers), reconstituted reporter 
activity can be measured for example by a colometric reaction, fluorescence, luminescence 
or survival rates, respectively. PCAs make it possible to monitor protein-protein interactions 
in the natural context where they occur in a living cell. Furthermore, they are not restricted to 
soluble proteins, though even membrane anchored proteins can be studied. The first 
example of a PCA was described by Johnsson and Varshavsky utilizing the C-terminal and 
N-terminal fragment of ubiquitin fused to the proteins of interest as sensor for protein 
interaction (Johnsson and Varshavsky, 1994). Interaction leads to reconstitution of the native 
ubiquitin, which is rapidly cleaved in vivo by ubiquitin specific proteases with release of a free 
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reporter. In the subsequent years the number of reporter proteins increased continuously 
providing different readouts for the desired applications. Examples for reporter proteins 
allowing in time readout and quantification by substrate application are the dihydrofolate 
reductase (DHFR) (Pelletier, 1997; Pelletier, Campbell-Valois, and Michnick, 1998), β-
galactosidase and the TEM-1 β-lactamase (Galarneau et al., 2002; Pelletier, 1997; Wehrman 
et al., 2002). PCAs using fluorescent reporter proteins like GFP (Ghosh et al., 2000) and 
colour and behavioural variants (Hu, Chinenov, and Kerppola, 2002; Remy and Michnick, 
2004; Ueyama et al., 2008) allowing direct readout without additional substrate addition and 
are also known as bimolecular fluorescence complementation (BiFC).  
The uses of PCAs are increasing, spanning different areas such as the study of biochemical 
networks, screening for protein inhibitors and determination of drug effects. PCAs were used 
for example to identify the interaction partners of the protein kinase PKB/Akt (Remy and 
Michnick, 2004) and also to elucidate Wnt/β-catenin signalling pathways including a library 
screen to identify compounds that induce β-catenin nuclear accumulation (Verkaar et al., 
2010). The applications of PCAs are not limited to cellular context. Hashimoto and 
colleagues (Hashimoto et al., 2009) describe an in vitro PCA in which fusion proteins are 
produced by wheat germ cell-free protein synthesis system and combined in a high-
throughput format to screen for protein-protein interaction inhibitors. In our lab, we recently 
established a cell-free TEM-1 β-lactamase based PCA setting using partially purified proteins 
for the pUL50/pUL53 interaction of HCMV (Schnee et al., 2012). 
 
1.4.2. Beta-lactamase as reporter enzyme in PCA 
The TEM-1 β-lactamase is the product of the ampicilin resistance gene (ampr) of E.coli and 
fulfils the essential criteria as reporter enzyme in a PCA. It is small and monomeric, non-toxic 
and can be expressed in prokaryotic as well as in eukaryotic cells (Matagne, Lamotte-
Brasseur, and Frere, 1998; Philippon et al., 1998). In its natural context it is secreted in the 
periplasmic space due to a signal peptide in the first 23 aa (Kadonaga et al., 1984). In PCA a 
29 kDA isoform of TEM-1 β-lactamase (Bla) is used which lacks the secretory signal 
sequence (Zlokarnik et al., 1998). Since no orthologs of β-lactamase exist in eukaryotic cells 
there is no problem of background activity which increases the specificity of the PCA. 
Furthermore there is a versatile repertory of lactamase substrates available. For Bla based 
PCAs the fluorescent CCF2/AM (Zlokarnik et al., 1998) and the chromogenic cephalosporin 
nitrocefin (Figure 6B) (O'Callaghan et al., 1972) are the commonly used substrates for 
readout and quantitative assessment. Both are membrane permeable allowing to study 
interactions in intact cells as well as in lysates. 
The first Bla based PCA was suggested by Garlaneau and Wehrman (Galarneau et al., 
2002; Wehrman et al., 2002). They split the β-lactamase enzyme into a N-terminal (BlaN) 
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and a C-terminal (BlaC) fragment after aa 197 and fused the parts to some test protein 
interactions to analyze background and restoration of reporter activity upon interaction 
(Figure 6A).  
In our lab, a cell-based β-lactamase PCA was established to investigate the interaction of the 
herpesvirus UL31 and UL34 protein homologs (Schnee et al., 2006).  
 
Figure 6: β-Lactamase (Bla) based protein fragment complementations assay (PCA). (A) 
Schematic representation of the PCA strategy used to study protein-protein interactions. Interaction 
between protein A and B leads to proximity of the β-lactamase fragments (BlaN and BlaC) allowing 
correct folding and reconstitution of the enzyme activity. (B) Structure of the chromogenic substrate 
nitrocefin which changes from yellow to red when hydrolyzed by β-lactamase activity (Figures adapted 
from Garlaneau et al., 2002). 
 
Recently we established a cell-free PCA setting for the pUL50/pUL53 interaction of HCMV 
(Schnee et al., 2012). The proteins fused to fragments of the β-lactamase are thereby 
produced in E.coli and purified via an introduced His-tag by Ni2+-NTA agarose. This PCA was 
used so far to further characterize the binding site of pUL53 for pUL50 and to identify 
inhibitory peptides of this interaction. 
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1.5 Aims of this work 
Since viral protein-protein interactions are attractive drug targets, we aimed to develop a 
systematic approach by which small molecular inhibitors for essential viral protein-protein 
interactions can be identified. 
 
We hypothesized that TEM-1 β-lactamase based protein fragment complementation assay 
may serve as a platform in which a simple cell-based assay can be used to test the feasibility 
of the PCA and if successful such a PCA can be systematically developed to an in vitro 
assay to screen for inhibitors. 
 
In this work we specifically aimed to establish a screen for specific inhibitors of the 
pUL50/pUL53 interaction by a high-throughput in vitro assay system. This interaction was 
chosen as potential specific antiviral target because the pUL50 and pUL53 protein families 
are unique to herpesviruses. Furthermore the interaction domains of pUL50 and pUL53 have 
been studied and it was shown in MCMV and HCMV that single or small clustered amino 
acid substitutions in these proteins lead to a strong decrease or a total loss of this 
heterodimerization (Bubeck et al., 2004; Lotzerich, Ruzsics, and Koszinowski, 2006; Sam et 
al., 2009) resulting in a failure of virus production (Bubeck et al., 2004) which suggests that a 
small molecule could also disrupt this interaction.  
 
Therefore, a cell-free assay should be applied in compound library of small molecules to 
identify inhibitory lead compounds for the pUL50/pUL53 interaction. This included in the first 
part of this thesis (i) the standardization of the assay conditions for high-throughput 
screening (HTS), (ii) the HTS of 4,000 small molecules and (iii) characterization of the lead 
compounds in the cellular and viral context.  
 
A further aim of this work was (iv) to establish a PCA for another essential viral protein-
protein interaction which can be used in future HTS screens. Thereby, the interaction of 
pUL94/pUL99 which plays an essential role during secondary envelopment process of 
cytoplasmic capsids (Phillips and Bresnahan, 2011a; Silva et al., 2003) was chosen as 
potential drug target. In our lab, the interaction of the MCMV homologs pM94 and pM99 was 
previously investigated thereby identifying small insertion mutants of pM94 which lost pM99 
binding (Maninger et al., 2011) suggesting a limited binding surface. The interaction was first 
established for the MCMV and HCMV homologs in the cell-based PCA system to investigate 
compatibility with the reporter fragment tags, specificity and background before HCMV 
constructs were transferred to the bacterial expression system. 
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2. Material 
2.1 Chemicals 
Except as noted otherwise chemicals were derived from the companies Roche 
(Mannheim; D), Merck (Darmstadt; D), Roth (Karlsruhe; D), Serva (Heidelberg;D), Sigma- 
Aldrich (Steinheim; D), Fluka Chemie GmbH (Karlsruhe; D) und Invitrogen (Karlsruhe; D). 
Lactamase substrate nitrocefin was derived from Oxoid (Wesel; D). Chemical compounds for 
inhibitor screen were provided from EMC microcollections (Tübingen; D). 
 
2.2 Enzymes 
2.2.1 Restriction endonucleases 
All used restriction endonucleases were derived from New England Biolabs (NEB) 
(Frankfurt/Main; D) or Fermentas (St. Leon-Rot; D) and applied referring to the 
manufacturer’s instructions. 
2.2.2 Other enzymes 
Antarctic Phosphatase    New England Biolabs (NEB) 
BP Clonase™ II enzyme mix    Invitrogen, Karlsruhe; D 
Klenow fragment     New England Biolabs (NEB) 
LR Clonase™ II enzyme mix    Invitrogen, Karlsruhe; D 
Proteinase K solution     Invitrogen, Karlsruhe; D 
T4-DNA Ligase      New England Biolabs (NEB) 
TEM-1 β-lactamase     Abcam, Cambridge; UK 
 
2.3 Devices 
Bacterial shaker ISF-1-W    Kühner, Adolf AG, Birsfelden; CH 
Centrifuge 5417 R     Eppendorf; D 
Confocal microscope Axiovert 200M   Zeiss, Jena; D 
Developing machine Optimax TR   MS Laborgeräte, Wieloch; D 
Eagle-Eye imaging system    BioRad, München; D 
ELISA plate reader (Versamax)   Molecular Devices, CA; USA 
Fluorescence microscope 1x71   Olympus, Hamburg; D 
Gene PulserTM     BioRad, München; D 
Incubator B5050E     Heraeus Instruments, Osterode; D 
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Mini-PROTEAN3 Cell     BioRad, München; D 
Light Cycler      Roche, Mannheim; D 
Luminometer      Perkin Elmer, Boston, MA; USA 
PCR machine      Roche, Mannheim; D 
PerfectBlueTM vertical electrophoresis system Peqlab, Erlangen; D 
Roller mixer SRT     Stuart, Staffordshire; UK 
Semi-Dry-Transfer Cell (Trans-BlotSD)  BioRad, München; D 
Sonifier 450       Branson, Danbury, CT; USA 
 
2.4 Consumables 
Amersham HybondTM-P membrane   GE Healthcare, Buckinghamshire; UK 
Cell culture dishes (20 cm2, 55 cm2, 145 cm2) Becton Dickinson, Heidelberg; D 
Cell culture plates (6-, 12-, 24-, 48-, 96-well) Becton Dickinson, Heidelberg; D 
Cell scratcher      Costar, Bodenheim;D 
Chemiluminescence film (HyperfilmTMECL)  GE Healthcare, Buckinghamshire; UK 
Electroporation cuvettes    BioRad, München; D 
Falcons conical tubes    Becton Dickinson, Heidelberg; D 
Pipettes (5 ml, 10 ml, 25 ml)    Sarstedt, Nümbrecht; D 
Reaction tubes (1.5 ml, 2 ml)    Eppendorf, Hamburg; D 
Whatman paper     Macherey-Nagel, Düren; D 
 
2.5 Commercial kits 
Cell Titer 96® Aqueous One  
Solution Cell Proliferation Assay   Promega, Madison; USA 
DNeasy Blood & Tissue Kit    QIAGEN, Hilden; D 
ECL plus Western Blotting Detection System GE Healthcare, Buckinghamshire; UK 
Expand High Fidelity PCR system   Roche, Mannheim, D 
QIAquick Gel Extraction Kit    QIAGEN, Hilden; D 
IllustraTM plasmidPrep Mini Spin Kit  GE Healthcare, Buckinghamshire; UK 
Luciferase assay system    Promega, Madison, USA 
Nucleobond® Xtra Midi    Macherey-Nagel, Düren; D 
QuantiTect SYBR Green PCR Kit   QIAGEN, Hilden; D 
QIAquick PCR purification Kit   QIAGEN, Hilden; D 
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2.6 Antibodies 
2.6.1 Primary antibodies 
2F12: mouse monoclonal antibody specific for HCMV glycoprotein gB (Biozol, Echingen; D). 
CMV pp52 (CH16): mouse monoclonal antibody specific for pp52 (UL44) (Santa Cruz 
Biotechnology, Heidelberg; D). 
cmv: mouse monoclonal antibody specific for HCMV immediate early protein1 (Perkin Elmer, 
Boston, MA; USA). 
3F10: rat monoclonal antibody specific for HA-tag (Roche, Mannheim; D). 
A2066: rabbit polyclonal antibody specific for actin (Sigma-Aldrich, Taufkirchen;D). 
F3165: mouse monoclonal M2 antibody directed against FLAG-tag (Sigma-Aldrich, 
Taufkirchen; D). 
 
2.6.2 Secondary antibodies 
All secondary antibodies coupled to horseradish peroxidise (HRP) were purchased from 
Dianova (Hamburg; D). 
Anti-mouse IgG (H+L), HRP coupled 
Anti-rabbit IgG (H+L), HRP coupled 
Anti-rat IgG (H+L), HRP coupled 
 
Anti-rabbit IgG, Alexa 555 conjugate  Invitrogen, Karlsruhe; D 
Anti-rat IgG; Alexa 488 conjugate   Invitrogen, Karlsruhe; D 
 
2.7 Bacteria 
ccdB Survival Cells     Invitrogen, Karlsruhe; D 
DH10B (recA-)      Invitrogen, Karlsruhe; D 
Pir1       Invitrogen, Karlsruhe; D 
BL21-CodonPlus (DE3)-RIL    Stratagene, Amsterdam; Netherlands 
 
2.8 Cells 
HFF:  Primary human foreskin fibroblast cells  PromoCell, Heidelberg; D 
293T: Human kidney carcinoma cells  ATCC CRL-11268 
MEF: Mouse embryonic fibroblasts   isolated from BALB/c mice  
U2OS: Osteosarcoma from the tibia of   ATCC HTB-96 
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a human female 
2.9 Viruses 
TB40-BAC4  wildtype HCMV (Sinzger et al., 2008) 
TB40-BAC4∆UL5-9/Luc 
(HCMV-luc) HCMV mutant expressing firefly luciferase 
under the control of SV40 promotor 
(Scrivano et al., 2011) 
 
2.10 Oligonucleotides  
All used oligonucleotides were synthesized by Metabion (Martinsried; D). 
 
2.10.1 Oligonucleotides for used for cloning 
M94del1-13attB-for: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATCAGTAGGTTCGTCCAG 
M94attB-rev: GGGGACCACTTTGTACAAGAAAGCTGGGTACATGTGCTCGAGAACGAT 
 
UL94attB-for: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGCTTGGCGCAGCGGG 
UL99attB-rev: GGGGACCACTTTGTACAAGAAAGCTGGGTATTAGTGCACTAGGTTCTT 
 
M94attb-for: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGCGACGTCCAGACTA 
 
UL99attB-for: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGGTGGCGAACTCTGC 
UL99attB-rev: GGGGACCACTTTGTACAAGAAAGCTGGGTATTAAAAGGACAAGGGGGC 
 
Acc65I-CUL99del-for: 
AGTTCGGTACCACGTCCGGTGAGCCCCTGAAAGGTTCCGACGAAGGGGAGGACGATGA 
BlpI-CUL99-rev: CGGCAGTCGCTTAGCCACCA 
 
BglII-UL94-for: GGCGGCGGATCCAGATCTATGGCTTGGCGCAGCGGGCTTT 
NotI-UL94-rev: GTGGTGCTCGAGTGCGGCCGCGTGCACTAGGTTCTTAAGC 
 
BamHI-CUL99His-for: GGCGGCGGATCCATGGGTGGCGAACTCTGCAA 
NotI-CUL99-rev: GCTCGAGTGCGGCCGCAAAGGACAAGGGGGCGGC 
 
EcoRV-UL50HA-for: ATTCTGCAGATATCATGGAGATGAACAAGGTTCTCCA 
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NsiI-UL50HA-rev: 
GCCCTCTAGATGCATTCAAGCGTAGTCGGGCACGTCGTAGGGGTAGTCGCGGTGTGCGGAGCG
TGTCGG 
 
EcoRV-FlagUL53-for: 
ATTCTGCAGATATCATGGATTACAAGGATGACGACGATAAGTCTAGCGTGAGCGGCGTGCGCAC
G 
NsiI-FlagUL53-rev: GCCCTCTAGATGCATTCAAGGCGCACGAATGCTGTTGAG 
 
2.10.2 Real time PCR primer 
 
HVIPO1: TCATCTACGGGGACACGGAC 
HVIPO2: TGCGCACCAGATCCACG 
GAPDH-for: TGGTATCGTGGAAGGACTCA 
GAPDH-rev: CCAGTAGAGGCAGGGATGAT 
2.11 Plasmids 
2.11.1 Commercial available and published plasmids 
Litmus28  NEB, Frankfurt/Main; D  
pDONRTM221  Invitrogen, Karlsruhe; D 
pDONR TM221-M50      provided by J. Haas 
pDONR TM221-M53   provided by J. Haas 
pDONRTM221-M94  provided by J. Haas 
pDONRTM221-M99  provided by J.Haas 
pEF5/FRT-V5-DEST      Invitrogen, Karlsruhe; D 
pEPkan-I-SceI      Tischer et al., 2006 
pET24-NUL50-His  Schnee et al., 2012 
pET24-CUL53-His  Schnee et al., 2012 
pL-HA-N  Schnee et al., 2006 
pL-HA-C  Schnee et al., 2006 
pO6T-C-M53  Schnee et al., 2006 
pO6T-C-UL53  Schnee et al., 2006 
pO6T-N-M50DM      Schnee et al., 2006  
pO6T-N-UL50       Schnee et al., 2006 
pOriR6K-M94i13 Maninger et al., 2011 
pOriR6K-M99FLAG Maninger et al., 2011 
pOriR6K-zeo-ie  Bubeck et al., 2004 
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Bacterial artificial chromosomes (BACs): 
TB40-BAC4  Sinzger et al., 2008 
pSM3fr  Wagner et al., 1999 
 
2.11.2 Plasmids constructed over the project 
pL-HA-Nf and pL-HA-Cf: 
pL-HA-C and pL-HA-N were digested with AvrII and AflII and inserted in each case in  
Litmus28 predigested with AvrII and AflII. 
 
pEF5/FRT-V5-Nf-DEST and pEF5/FRT-V5-Cf-DEST 
To create Gateway® compatible BlaN- and BlaC- fusion vectors, respectively, pL-HA-Nf  
and pL-HA-Cf were digested with AflII, blunted by Klenow and finally digested with XbaI. The 
inserts were then ligated to the vector backbone of pEF/FRT-V5-DEST which resulted from 
digestion with Acc65I, fill-in and final cleavage with SpeI. 
 
pDONR 221-UL94 
The ORF UL94 in TB40-BAC4 was PCR amplified by the forward primer UL94attB-for and 
the reverse primer UL94attB-rev. The PCR products were then recombined by BP Clonase™ 
II enzyme reaction with pDONR 221 resulting in pDONR 221-UL94. 
 
pDONR 221-M94i13 
The sequence of the dominant negative M94i13 mutant was PCR amplified from pOriR6K-
M94i13 with the primer pair M94attB-for and M94attB-rev. The PCR product was finally 
recombined by BP Clonase™ II enzyme reaction with pDONR 221 to result in pDONR 221-
M94i13. 
 
pDONR 221-UL99 
The UL99 ORF of TB40-BAC4 was PCR amplified by the primer pair UL99attB-for and 
UL99attB reverse and the resulting PCR product was recombined by BP Clonase™ II 
enzyme reaction with pDONR 221 resulting in pDONR 221-UL99. 
 
pO6T-Nf-M50, pO6T-Nf-M94, pO6T-Nf-M94i13, pO6T-Nf-UL94 
To fuse the N-terminal PCA fragment of β-lactamase to the different ORFs, pDONR 221-
M50, pDONR 221-M94, pDONR 221-M94i13 and pDONR 221-UL94 were recombined by LR 
Clonase™ II enyme reaction with pEF5/FRT-V5-Nf-DEST, respectively. 
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Fusion constructs were further digested with AgeI, blunted by Klenow and finally digested by 
AflII to create an insert (smaller band) which was subloned in the vector backbone of pO6T-
C-M53 which was pre-digested by NsiI, filled-in and then digested with AflII to result in pO6T-
Nf-M50, pO6T-Nf-M94, pO6T-Nf-M94i13 and pO6T-Nf-UL94, respectively. 
 
pO6T-Cf-M53, pO6T-Cf-M99, pO6T-Cf-UL99 
To fuse the C-terminal PCA fragment of β-lactamase to the different ORFs and mutants 
pDONR 221-M53, pDONR 221-M99 and pDONR 221-UL99 were recombined by LR 
Clonase™ II enyme reaction with pEF5/FRT-V5-Cf-DEST, respectively. 
Fusion constructs were further digested with AgeI, blunted by Klenow and finally digested by 
AflII to create an insert (smaller band) which was subloned in the vector backbone of pO6T-
C-M53 which was pre-digested by NsiI, filled-in and then digested with AflII to result in pO6T-
Cf-M53, pO6T-Cf-M99, pO6T-Cf-UL99, respectively. 
 
pO6T-Cf-UL99del22-43 
To have a non-binding control of UL99 for the cell-based PCA a PCR product was generated 
using the primer pair Acc65I-CUL99del-for and BlpI-CUL99-rev and pO6T-Cf-UL99 as 
template. As a second step the resulting PCR product and the vector pO6T-Cf-UL99 were 
digested with Acc65I and BlpI and fused by ligation resulting in pO6T-Cf-UL99del22-43. 
 
pO6T-Nf-M50DM 
pO6T-N-M50DM was digested with NarI and AhdI and the smaller fragment was inserted into 
the pO6T-Nf-M50 vector backbone which was also predigested with the same enzymes to 
result in pO6T-Nf-M50DM. 
 
pOriR6K-UL50-HA 
The UL50 ORF was amplified from TB40-BAC4 with the primer pair EcoRV-UL50HA-for and 
NsiI-UL50HA-rev. The resulting PCR product was then cleaved with EcoRV and NsiI and 
inserted in the correspondingly treated pOriR6K-zeo-ie to result in pOriR6K-UL50-HA. 
 
pOriR6K-FLAG-UL53 
The UL53 ORF was amplified from TB40-BAC4 with the primer pair EcoRV-FlagUL53-for 
and NsiI-FlagUL53-rev. The resulting PCR product was the cleaved with EcoRV and NsiI and 
inserted in the correspondingly treated pOriR6K-zeo-ie to result in pOriR6K-FLAG-UL53. 
 
pET24-N-UL94-His 
The ORF of UL94 was amplified from TB40-BAC4 with the primer pair BglII-UL94-for and  
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NotI-UL94-rev. The resulting PCR product was then cleaved by BglII and NotI and then 
inserted into the BamHI/NotI treated pET24-N-UL50 to resul in pET24-N-UL94-His. 
 
pET24-C-UL99-His 
The ORF of UL99 was amplified with the primer pair BamHI-CUL99His-for/NotI-CUL99-rev. 
The PCR product was then digested with BamHI and NotI and inserted into BamHI/NotI 
treated pET24-C-UL53-His. 
 
pET24-C-UL99del22-43-His 
The sequence of the deletion mutant of UL99 was amplified from pO6T-Cf-UL99del22-43 by 
the primer pair BamHI-CUL99His-for and NotI-CUL99-rev. The PCR product was then 
cleaved by BamHI and and NotI and inserted into BamHI/NotI treated pET24-C-UL53-His. 
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3. Methods 
3.1 Bacterial cell culture 
All bacteria were grown either in suspension (LB medium) or on agar-plates (LB agar). For 
plasmid or BAC selection the growth media comprised the appropriate antibiotics in distinct 
concentration (see below). Cells harbouring a plasmid were grown at 37 °C, whereas BAC-
containing cells were grown at 32 °C to enable slower division and proper replication. Cell 
density in suspension was determined by measuring the optical density at 600 nm, while 1 
unit of OD600 corresponds to approximately 1 x 10
8 cells. 
LB medium (1 l)  LB agar (500 ml)  Antibiotics 
10 g Bacto tryptone  7.5 g agar    ampicillin: 50 µg/ml 
5 g Bacto yeast extract in 500 ml LB medium  chloramphenicol: 25 µg/ml 
5 g NaCl       kanamycin: 50 µg/ml 
        zeocin: 30 µg/ml 
 
3.1.1 Glycerol stocks of bacteria 
To maintain a culture of bacteria bearing the plasmid of interest, glycerol stocks were 
prepared by adding 500 µl glycerol (50%) to 500 µl bacterial culture. The stocks were stored 
at -80 °C. 
 
3.1.2 Preparation of chemocompetent bacteria 
All preparation and centrifugation steps were done on ice or 4 °C using pre-cooled pipettes 
and solutions. 150 ml of LB medium was inoculated with 1 ml overnight culture and grown at 
37 °C until the suspension reaches an OD600 of 0.5. Bacteria were pelleted by centrifugation 
for 10 min at 6,000 x g and resuspended in 20 ml Tfb I buffer. After 50 min incubation on ice, 
bacteria were pelleted again, resuspended in 2 ml Tfb II and snap frozen in liquid nitrogen as 
100 µl aliquots and stored at -80 °C. 
Tfb I (pH 5.2)      Tfb II (pH 7.0) 
100 mM RbCl2     10 mM MOPS pH 7.0 
50 mM MnCl2      10 mM RbCl2 
30 mM KAc      75 mM MnCl2 
10 mM CaCl2      15% glycerol 
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3.1.3 Transformation of chemocompetent bacteria 
To introduce plasmids into chemocompetent bacteria, 4 µl of a ligation mix or 30 ng of a 
plasmid were added to 100 µl chemocompetent bacteria and incubated on ice for 30 min. 
After that, samples were subjected to a heat-shock of 1 min at 42 °C followed by another 2 
min of incubation on ice. Bacteria were suspended in 1 ml antibiotic-free LB medium and 
shaked at 37 °C for 1 h. 200 µl were plated on LB agar plates containing the appropriate 
antibiotics and incubated overnight at 37 °C. 
 
3.1.4 Preparation of electrocompetent bacteria 
All preparation steps were done on ice or 4 °C using pre-cooled pipettes and solutions. 150 
ml of LB medium was inoculated with 1 ml overnight culture and grown at appropriate 
temperature until the suspension reaches an OD600 of 0.5. Cultures were then cooled on ice 
for 15 min and bacteria were pelleted by centrifugation for 10 min at 6,000 x g. To eliminate 
salts and medium components, bacteria were washed three times with 100 ml 10% glycerol. 
Finally, the bacterial pellet was resuspended in 1 ml of 10% glycerol and aliquots of 50 µl 
were snap frozen and stored at -80 °C. 
 
3.1.5 Transformation of electrocompetent bacteria 
For introduction of plasmids into bacteria, 50 µl electrocompetent bacteria were thawed for 5 
min on ice. About 4 µl of a ligation mixture or 20 ng of a plamid were pipetted to the bacteria 
cells and then the mixture was transferred into a pre-cooled Gene Pulser® bulb. After 
electrotransformation (pulse duration: 4.5 ms, 2.5 kV, 200 Ohm, 25 mFD) the cells were 
immediately resuspended in 1 ml LB medium without antibiotics and transferred to an 2 ml 
Eppendorf reaction cup. The cells were incubated in the Thermomixer 1 h at 37°C under 
permanent shaking. After that, 100 µl of the bacteria suspension was plated on pre-warmed 
agar culture plates comprising the adequate antibiotics and incubated overnight at 37 °C. 
 
3.2 Isolation and purification of DNA 
3.2.1 Small scale preparation of plasmid DNA 
For small scale analysis, plasmid DNA from a 5 ml overnight culture was isolated by using 
the IllustraTM plasmidPrep Mini Spin kit from GE Healthcare following the manufacturer’s 
protocol. The plasmid DNA was eluted from the binding columns with 100 µl distilled water. 
10 µl were used for restriction pattern analysis. 
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3.2.2 Small scale preparation of BAC-DNA 
Bacterial pellets from 10 ml overnight cultures were resuspended in 150 µl P1 buffer 
(Qiagen). Preparations were lysed by addition of 150 µl P2 buffer (Qiagen) and incubation for 
5 min at RT before they were neutralized by application of 300 µl P3 buffer (Qiagen). 
Samples were incubated 10 min on ice and precipitations were pelleted by centrifugation at 
20,000 x g for 10 min at 4 °C. Cleared supernatants were transferred to new reaction tubes, 
mixed with 900 µl phenol/chlorophorm/alcohol (25/24/1), and centrifuged for 5 min at 20,000 
x g. The upper phase was transferred to a new reaction tube and comprehending BAC-DNA 
was precipitated by addition of 900 µl isopropanol and centrifugation at 20,000 x g for 20 min. 
DNA pellets were washed with 70% ethanol and resuspended in ddH2O.  
 
3.2.3 Large scale preparation of plasmid and BAC-DNA 
Large scale preparations of plasmid and BAC DNA were performed using the Nucleobond® 
Xtra Midi Kit from Macherey-Nagel. A volume of 200 ml of a bacterial overnight culture was 
used for DNA isolation according to the manufacturer’s protocol. The dried plasmid DNA 
pellet was resuspended in 200 µl distilled water and further analyzed by restriction enzyme 
digest or stored at -20 °C. 
3.3 Analysis of DNA 
3.3.1 Restriction enyme digest 
For restriction enzyme digest of DNA restriction endonuncleases from NEB were used 
according to the manufacturer’s instructions. Digests for analytical purposes were performed 
with 500 ng (plasmid) to 1.5 µg (BAC-DNA) or for preparative applications with 5 µg DNA, 
respectively, and the reaction was incubated for 1-3 h at the recommended temperature.  
3.3.2 Agarose gel electrophoresis 
DNA fragments obtained by restriction digest from plasmids were separated and analyzed by 
gel electrophoresis in a 1-2% agarose/ TAE or for BAC DNA in a 0.8% agarose/TBE gel, 
respectively. Gels were run 20 min at 120 V or 16 h at 80 V. For detection of the DNA bands 
the gels comprised ethidium bromide in a final concentration of 1 µg/ml which was added 
before poring. Stained bands were visualized by UV light in an Eagle-Eye imaging system 
from BioRad. 
 
50 x TAE buffer (pH 7.3)  10 xTBE buffer  6 x DNA loading buffer 
2 M Tris    900 mM Tris   15% Ficoll  
0.25 M Na-acetate   900 mM boric acid  Orange G  
50 mM EDTA    25 mM EDTA 
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3.3.3 Isolation of DNA fragments from agarose gels 
To extract the respective DNA fragment for further cloning steps, the stained band was 
exicised under weak UV light from the agarose gel. The DNA was purified from agarose 
using the QIAquick Gel Extraction Kit from QIAGEN following the manufacturer’s protocol. 
The purified DNA was eluted with 30 µl distilled H2O. 
 
3.3.4 Dephosphorylation of DNA fragments 
To suppress re-circularization of cleaved, linearized vector DNA, the terminal 5´-phosphate 
groups were removed by using Antarctic Phosphatase (AP) from NEB.  
Per 1 µg DNA in appropriate buffer conditions 1 unit of AP was applied. The reaction mixture 
was incubated at 37 °C for 30 min and finally heat-inactivated at 65 °C for 10 min. 
 
3.3.5 Blunting of DNA overhangs by Klenow 
DNA overhangs were blunted by using the Klenow fragment of NEB. For that, 1 µg DNA was 
incubated with 5 units of Klenow and 100 µM dNTP in 1 x NEB buffer 2 for 15 min at RT. 
After this, DNA was immediately purified from the enzyme by using QIAquick PCR 
purification Kit. 
3.3.6 Polymerase Chain Reaction (PCR) 
To amplify arbitrary pieces of DNA, a PCR was performed. The reaction was done in a total 
volume of 50 µl using the Expand High Fidelity PCR system from Roche. A standard PCR 
reaction mixture is shown below. 
 
PCR reaction mixture 
10-50 ng of template DNA 
500 nM of each oligonucleotide primer 
250 µM dNTPs 
Expand High Fidelity Polymerase buffer (1 x) 
3.5 units of High Fidelity Polymerase 
 
To reduce non-specific amplification, a touchdown PCR was performed with the following 
conditions (Table 1). Time is variable in the elongation steps (4. + 7.) depending on the 
length of the resulting PCR product. For every further 500 bp the polymerase needs another 
30 sec for elongation. 
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 Step Temperature Time Cycles 
1. initial denaturation 94 °C 5 min  
2. denaturation 94 °C 30 sec  
3. annealing 62-45 °C 30 sec  
4. elongation 72 °C 30 sec-2 min -1 °C every cycle; 17 x back to 2. 
     
5. denaturation 94 °C   
6. annealing 45 °C 30 sec  
7. elongation 72°C 30sec-2 min  
8. final elongation 72°C 5 min 18 x back to 5. 
9. end 4 °C ∞  
Table 1: TD-PCR program. 
 
The obtained PCR products were purified using the QIAquick Purification Kit from QIAGEN 
following the manufacturer’s protocol. 
 
3.3.7 Ligation of DNA fragments 
Ligation reactions were performed in a total volume of 20 µl comprising 100 ng vector mixed 
at a molecular ratio of 1:3 with the insert, 2 units of T4 DNA ligase and T4 ligase reaction 
buffer. The reaction was incubated overnight at 16 °C or for 2 h at RT and then added to 
competent bacteria for transformation. 
 
3.3.8 BP reaction (Gateway® system) 
A BP reaction was performed to create a Gateway® (Invitrogen) entry clone from an attB-
flanked PCR product. Therefore a reaction mixture comprising 15-150 ng attB-PCR product, 
150 ng pDONR 221 (150 ng/µl) TE buffer, 2 µl BP Clonase™ II enzyme filled up to 10 µl with 
TE buffer (pH 8.0) was incubated at RT for 1 h. To terminate the reaction, 1 µl of the 
Proteinase K solution was added the mix and incubated at 37°C for 10 min. 1 µl from the 
reaction mix was used for transformation into competent cells. 
 
3.3.9 LR reaction (Gateway® system) 
A LR reaction was performed to transfer a gene from a Gateway® entry clone to destination 
vector. Therefore a reaction mixture comprising 15-150 ng donor vector (pDONR 221-gene), 
150 ng destination vector (pEF5/FRT-V5-Nf-DEST and pEF5/FRT-V5-Cf-DEST) and 2 µl LR 
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Clonase™ II enzyme filled up to 10 µl with TE buffer (pH 8.0) was incubated at RT for 1 h. To 
terminate the reaction, 1 µl of the Proteinase K solution was added the mix and incubated at 
37°C for 10 min. 1 µl from the reaction mix was used for transformation into competent cells. 
 
3.3.10 DNA sequencing 
DNA sequencing was performed by GATC (Konstanz; D) and by Sequiserve (Vaterstetten; 
D). Sequences were aligned and verified using Vector NTI AdvanceTM software. 
 
3.3.11 Quantitative real-time PCR  
In order to quantify viral genomes, total DNA was extracted from infected HFF using the 
DNeasy Blood & Tissue Kit from QIAGEN according to the manufacturer’s instructions. 
Quantitative real-time PCR was performed on a Light Cycler from Roche using 5 µl of DNA, 
15 µl reaction mixture of QuantiTect SYBR Green PCR master mix from QIAGEN and 0.5 µM 
of the primers in each reaction. For quantification of the viral DNA load, primers amplifying 
the viral DNA polymerase gene region UL54 (Primers: HVIPO1 and HVIPO2) and primers 
against GAPDH as endogenous reference (Primers: GAPDH-for, GAPDH-rev) were used. 
Each sample was analyzed in duplicates. PCRs were subjected to 95 °C hot-start for 10 min, 
and SYBR Green incorporation was monitored for 45 cycles of 95 °C denaturation for 10 sec, 
58 °C annealing for 3 sec, and 72 °C elongation for 10 sec. The data were analyzed using 
the ∆∆Ct method. 
3.4 Analysis of proteins 
3.4.1 SDS-PAGE 
Protein samples were separated by polyacrylamide gel electrophoresis (PAGE). Before 
loading onto gels, protein samples were heated for 7 min at 95 °C in total lysis buffer. Gels 
were run in 1 x Laemmli buffer for approximately 1 h at 160 V. After electrophoresis, gels 
were either applied to Western Blot analysis for protein detection. 
4 x Stacking gel buffer    4 x Separating gel buffer 
0.5 M Tris     1.5 M Tris 
0.4% (v/v) SDS    0.4% (v/v) SDS 
pH 6.8      pH 8.8       
 
Stacking gel     Separating gel (10%,12%) 
2.5 ml Rothiphorese 30   3.3 ml/ 4 ml Rotiphorese 30 
3.75 ml 4 x stacking gel buffer  2.5 ml 4 x separating gel buffer 
9.75 ml dH2O     4.1 ml/3.4 ml dH2O 
0.1 ml APS (10%) solution   0.1 ml APS (10%) solution 
20 µl TEMED     3.3 µl TEMED 
 
1 x Laemmli buffer 
 Methods 
 
 39
50 mM Tris 
0.4 M glycine 
0.1% (w/v) SDS 
 
3.4.2 Coomasssie Blue Stain 
To visualize proteins in SDS gels, gels were incubated with staining solution for 30 min and 
subsequent treatment with destaining solution for several hours. 
Staining solution    Destaining solution 
50% (v/v) methanol    50% (v/v) methanol 
10% (v/v) acetic acid    10% (v/v) acetic acid 
0.1% (w/v) Coomassie blue R350 
 
3.4.3 Western Blot Analysis 
After separation of proteins by SDS-PAGE, proteins were transferred from the gel onto 
HybondTM-P membrane (GE Healthcare). For that, the membrane was activated 5 min by 
methanol and then equilibrated in blotting buffer. For transfer, the gel was placed on the 
activated membrane and covered on both sides by three layers of Whatman paper soaked in 
blotting buffer. The transfer was performed in a Semidry blotting apparatus (BioRad) for 30 
min at 18 V and room temperature. To block unspecific binding sites, blotted membranes 
were incubated for 1 h at room temperature with blocking buffer. After that, membranes were 
incubated with primary antibody diluted in blocking buffer overnight at 4 °C. After five washes 
with (5 x 10 min) with TBS-T, the membranes were incubated with horseradish-coupled 
secondary antibody diluted in TBS-T for 1-2 h at room temperature and were subsequently 
washed as described above. Chemiluminescence detection of bound antibodies was 
performed using ECL plus Western Blotting Detection System from GE Healthcare according 
to the manufacturer’s instructions. 
 
Blotting buffer   Blocking buffer   TBS-T 
25 mM Tris   150mM NaCl    150 mM NaCl 
190 mM glycine  10 mM Tris/HCl, pH 8.0  10 mM Tris/HCl, pH 8.0 
20% methanol  0.5% Tween 20   0.5% Tween 20 
    5% skimmed milk powder (w/v) 
 
3.4.4 Determination of protein concentration 
Protein concentrations were determined by the Bradfort method using Bradfort reagent 
(BioRad) according to the manufacturer’s protocol and a bovine serum albumin standard 
curve for calculation. 
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3.4.5 Indirect immunofluorescence 
For confocal laser scanning, cells were grown on 8 well µ-slides, fixed with 4% PFA and after 
washing with PBS permeabilized with 0.1% Triton-X-100 in PBS. After further washing, cells 
were blocked for 1 h at RT with 5% donkey serum in PBS (blocking solution). Primary 
antibodies were applied for 1 h in blocking solution at RT followed by 3 consecutive washings 
with PBS. Finally, cells were incubated with Alexa Fluor-conjugated secondary antibody in 
blocking solution. After a final extensive washing step, preparations were mounted on glass 
slides with Prolong Gold resin (Invitrogen) and analyzed on a confocal laser scanning 
microscope. 
3.5 Tissue culture 
3.5.1 Cultivation of mammalian cells 
All mammalian cell lines and primary cells grew adherent and were cultured at 37 °C and 
95% humidity in presence of 7% CO2 in DMEM supplemented with 10% FCS, 0.6% penicillin, 
1.3% streptomycin and 0.3 mg/ml L-glutamine. For passaging, the cell monolayers grown to 
confluency were washed once with PBS and detached from plates or flasks by incubation 
with 25% trypsin/EDTA solution for 2-5 min at RT. Trypsin reaction was stopped by adding of 
12 ml supplemented DMEM, cells were resuspended and the pertinent amount was brought 
to a plate with fresh medium. For maintenance, 293T cell were passaged every 3-4 days by 
a 1:6 split, whereas HFF and MEF cells were splitted 1:3 once a week. To ascertain defined 
cell numbers in a cell suspension and distinguish live and dead cells, cells were stained with 
trypan blue and transferred in a Neubauer chamber (Brand) for counting. All lines were 
tested regularly for mycoplasma contamination. 
3.5.2 Freezing of cells 
To maintain a stock of cells, cells were frozen and stored in liquid nitrogen. For that, cells 
were grown to a confluency of 90%, detached from the plates by trypsin treatment and 
pelleted by centrifugation (300 x g, 5 min). The cell pellet was carefully resuspended in 
freezing medium and transferred as 1 ml aliquots to cryo tubes (nunc). For gently freezing, 
tubes were transferred in isopropanol isolated cryo-boxes and stored at -80°C (-1 °C per 
hour). After 48-72 h tubes were stored in a liquid nitrogen tank. 
 
Freezing medium 
70% DMEM 
20% FCS 
10% DMSO 
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3.5.3 Thawing of cells 
Frozen aliquots from the liquid nitrogen tank were rapidly thawed in a 37 °C water bath  
As soon as possible, cells were resuspended in 10 ml supplemented fresh medium and 
centrifuged for 5 min at 300 x g. The pellet was taken up in 12 ml fresh supplemented 
medium and transferred to cell culture dishes. 
 
3.5.4 Cytotoxicity assay 
The influence of the chemical compounds on the viability of fibroblast cells during a 14-day 
incubation period was evaluated using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega), as described by the manufacturer. The assay depends on the 
bioreduction of an MTS tetrazolium compound (Owen’s reagent) by cells into a coloured 
formazan product that is soluble in tissue culture medium (Cory et al., 1991). This conversion 
is accomplished by NADPH or NADH produced by dehydrogenase enzymes in metabolically 
active cells (Berridge and Tan, 1993). 
Briefly, 96-well microtiter plates were seeded with 2 x 104 cells/well and incubated overnight. 
Compounds were added in different concentrations in duplicates while keeping the DMSO 
concentration constant at 1% throughout the whole plate. Cell viability was checked in two-
day intervals after substance application until day 14. Therefore, 20 µl CellTiter 96® AQueous 
One Solution Reagent was added to each well. After 1 h at 37 °C in a humidified, 5% CO2 
atmosphere, the absorbance at 490 nm was recorded using an ELISA plate reader. Data 
were normalized to background absorbance. 
 
3.5.5 Transfection of eukaryotic cells by FuGENE® HD 
Cells were seeded one day before transfection in 6-well plates or 8 well µ-slides. X µg DNA 
in 100 µl OptiMEM was mixed carefully with 2.5 x Xµl FuGENE® HD tranfection reagent 
(Roche) and incubated for 30 min at RT. Then the transfection mix was added drop-wise to 
the cell culture supernatants and the cells were incubated 24-48 h before they were 
harvested for further experiments. 
 
3.6 Virus culture 
3.6.1 Virus infection of cells 
For standard infection assays, cells were seeded on multi-well plates or dishes one day 
before infection to a confluency of around 90%. To infect, inocula were diluted in 
supplemented medium and applied to the cells. After incubation for 1.5 h at 37 °C inocula 
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were replaced by supplemented fresh medium and cells were incubated at 37 °C for the 
appropriate time. 
 
3.6.2 Growth curves 
The growth kinetics of HCMV in presence and in absence of chemical compounds was 
compared in multi-step growth conditions. HFF cells were seeded in 24-well plates (1 x 105) 
and were incubated overnight at 37 °C. The next day, cells were infected at an MOI of 0.2 
pfu/cell for 1.5 h at 37 °C. After that, cells were washed five times with fresh medium, 
medium containing chemical compounds in distinct concentrations or DMSO (mock control) 
(DMSO concentrations were kept constant at 1% in all wells) was added and cells were 
incubated at 37 °C. In distinct days post infection over a period of 8 days supernatants were 
harvested, stored at -80 °C and titers were determined. 
 
3.6.3 Titration of virus 
Quantification of infectious virus in supernatants was determined by the TCID50 assay 
(endpoint titration) (Reed, 1938) on fibroblast cells in 96-well plates. Cells were seeded on 
96-well plates one day before titration to 100% density. On the next day, cells were infected 
with serial dilutions of virus supernatant (10-1 to 10-8 in a volume of 100 µl of supplemented 
DMEM) in quadruplicates and were incubated for 8 days at 37 °C. To identify plaque positive 
wells cells were washed once with PBS and then fixed with 1 x crystal violet for 10 min at RT: 
After 3 consecutive washings with dH2O, positive and negative wells were counted under the 
microscope and titer values were calculated according to the Reed and Muench method. 
 
10 x Crystal violet 
10% para-formaldehyde in PBS 
1% crystal violet (w/v) 
 
3.6.4 Luciferase assay 
A luciferase assay was performed using HCMV expressing firefly luciferase (v-TB40-
BAC4∆UL5-9/Luc) to evaluate the influence of the chemical compounds on virus replication. 
The assay was performed in 96-well microtiter plates. Briefly, cells were infected with 
luciferase expressing reporter virus at an MOI of 0.01 pfu/cell for 1.5 h at 37 °C. After that, 
inocula were removed and 100 µl fresh medium, containing chemical compounds in different 
concentrations (DMSO concentration was kept constant at 1% throughout the plate) were 
added to the cells. After certain time points post infection, supernatants were removed and 
cells were directly lysed on the plate by adding 50 µl 1 x cell culture lysis reagent (Promega) 
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and incubated for 10 min at RT under permanent shaking. 5 µl of the lysates were 
subsequently transferred to white 96-well plates, mixed with 40 µl firefly substrate per well 
(Luciferase reporter assay, Promega) and the luciferase activity was measured for 5 sec in a 
luminometer. 
3.7 Bacterial expression 
3.7.1 Expression of heterologous proteins 
30-100 ng of plasmid DNA of bacterial expression vectors were transformed in 
chemocompetent BL21-(DE3)RIL (Stratagene) and cultured overnight at 37 °C on agar 
plates (Kan/Cam). The next day, 50 -100 colonies were scraped from the plate and used to 
inoculate 50 ml LB medium with appropriate antibiotics for overnight culture at 37 °C. 20 ml 
of the overnight culture was used to inoculate 2.5 l antibiotics containing LB medium and the 
bacterial culture was incubated at 37 °C until it reached an OD600 of 0.6. To cool down, 
culture flasks were put on ice for 15 min. Induction of heterologous proteins was induced by 
adding IPTG to a final concentration of 0.5 mM and cultures were shaked in an incubator at 
20 °C overnight. On the next day, cells were harvested by centrifugation (6000 x g, 4 °C, 20 
min) and pellets were resuspended in 35 ml lysis buffer, frozen in liquid nitrogen and stored 
at -80 °C.  
 
Lysis buffer 
300 mM NaCl 
50 mM Tris (pH 8.0) 
10 mM β-Mercaptoethanol 
 
3.7.2 Lysis of bacteria 
The bacterial solution was thawed in a 37 °C water bath and sonified by pulses of 1 sec and 
70% amplitude for 10 min (Sonifier 450, Branson) using a flat bottom tip. Subsequently, 
lysates were cleared by centrifugation at 15,000 x g for 30 min at 4 °C and applied to further 
purification steps or stored at -80 °C. 
 
3.7.3 Purification of His-tagged proteins 
All preparation steps were performed in the cold room with pre-cooled buffer solutions 
containing freshly added β-mercaptoethanol. 1.6 ml Ni-NTA agarose (QIAGEN) were loaded 
onto a 10 ml plastic column (BioRad) for sedimentation resulting in a bed volume of 800 µl. 
Agarose was washed two times with 10 ml dH2O and one time with 10 ml lysis buffer before 
the supernatant of the bacterial lysis was applied to the column. After loading and complete 
flow-through, the column was washed two times with 10 ml lysis buffer and one time with 4 
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ml lysis buffer containing 5 mM imidazole. His-tagged proteins were eluted from the column 
by application of 3 ml lysis buffer containing 250 mM imidazole, whereas only the first 1.5 ml 
of the flowthrough was collected. The protein elution was stored at -80 °C in 30% glycerol. 
3.8 Biochemical assays 
3.8.1 Nitrocefin assay in cell lysates 
Bla-fragment tagged constructs were single or co-transfected into 293T cells. After 48 h, cells 
were scraped from the plates, sedimented by centrifugation (300 x g, 5 min), washed with 
800 µl PBS and lysed with 150 µl 1 x luciferase reporter lysis buffer (Promega). After 30 min 
on ice, lysates were cleared by centrifugation for 10 min at full speed at 4 °C. For 
determination of β-lactamase activity, 50 µl of the lysates were transferred to a 96 well plate 
and mixed with 120 µl phosphate buffer (0.1 M, pH 7.0), 15 µl H2O and 15 µl nitrocefin (500 
mg/ml, Oxoid). Nitrocefin hydrolysis was determined as change in absorption at 495 nm in 
the linear range (milliabsorptions units/min) at a Versamax plate reader.  
 
3.8.2 Nitrocefin assay with purified proteins 
Proteins purified by Ni-NTA agarose were tested for Bla reconstitution in the presence of 15 
µl nitrocefin (500 mg/ml, Oxoid) filled up to a total volume of 200 µl with phosphate buffer (0.1 
M, pH 7.0). Nitrocefin hydrolysis was determined as change in absorption at 495 nm in the 
linear range (milliabsorptions units/min) in a Versamax plate reader (Molecular Devices). 
For the inhibitory screen, 10 µl screening compound (solved in DMSO; 10 µM final 
concentration) was mixed with the purified Bla-proteins, 15 µl nitrocefin (500 mg/ml, Oxoid) 
and filled up to a total volume of 200 µl with phosphate buffer (0.1 M, pH 7.0). The reaction 
was incubated for 40 min at 37 °C before 10 µl of stop solution (potassium clavulanate, 2 
µM) was added for reaction termination. Nitrocefin hydrolysis was determined by absorption 
measurement at 495 nm in a Versamax plate reader (endpoint determination, absorption at 
495 nm). 
 
3.8.3 Nitrocefin assay with β-lactamase 
To test the influence of the chemical screening compounds on the reporter β-lactamase, 10 
µl chemical compound (in DMSO, final screen concentration 10 µM) was mixed with 10 µl β-
lactamase enzyme solution (Abcam; 100 µg/ml, 0.1% BSA), 15 µl nitrocefin (500 mg/ml, 
Oxoid) and filled up to a total volume of 200 µl with phosphate buffer (0.1 M, pH 7.0). The 
reaction was incubated for 40 min at 37 °C before 10 µl of stop solution (potassium 
clavulanate, 20 µM stock) was added for reaction termination. Nitrocefin hydrolysis was 
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determined by absorption measurement at 495 nm in a Versamax plate reader (endpoint 
determination, absorption at 495 nm). 
 
3.9 Electron microscopy 
For electron microscopy, HFF cells were grown on carbon-coated sapphire discs (3 mm in 
diameter; Engineering Office M. Wohlwend GmbH, Switzerland) and infected at an MOI of 1. 
At 5 days post infection, the cells were frozen from the living state by high-pressure freezing 
with an HPF 01 apparatus (Engineering Office M. Wohlwend GmbH) and freeze substituted 
in acetone containing 0.1% (wt/vol) uranyl acetate, 0.2% (wt/vol) of osmium tetroxide, and 
5% (vol/vol) of water, as described previously (Buser et al., 2007). After embedding the 
samples in Epon, ultrathin sections were prepared on formvar coated single slot grids for 
transmission electron microscopy (TEM). Samples were imaged with the JEOL JEM-1400 
transmission electron microscope at an acceleration voltage of 80 kV. 
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4. Results 
4.1 Optimization of the in vitro NEC-PCA for high-throughput screening (HTS) 
In this work, a chemical compound library was screened for inhibitors for the interaction of 
the nuclear egress complex (NEC) proteins pUL50 and pUL53 of HCMV by a high-
throughput screen (HTS) approach based on a protein fragment complementation assay 
(PCA). A cell-based PCA of these two proteins and their homologs in other herpesviruses 
was established by Margit Schnee (Schnee et al., 2006) to elucidate conservation of this 
interaction between subfamilies. However, cell-based PCAs in general are not suitable for 
direct drug screening approaches due their experimental robustness such as dependency on 
eukaryotic cell transfection and cell lysis procedures for activity measurements. Furthermore, 
cell-based screening approaches suffer from excluding cytotoxic candidate compounds 
before screening which could lead to a miss of information about inhibiting structures. 
Therefore, the β-lactamase based PCA for the pUL50-pUL53 interaction was modified into a 
cell-free set-up, termed here in vitro NEC-PCA. Thereby, Bla-tagged NEC proteins were 
produced in an E.coli expression system and then combined in vitro. 
 
The constructs for E.coli expression of Bla-tagged NEC fusion proteins were designed and 
tested for specificity in a previous study (Schnee et al., 2012). 
 
Figure 7A shows a schematic representation of the expression strategy. For the pUL50 PCA 
construct (NUL50-His), the conserved region of pUL50 in the N-terminus (aa 1-172) was 
fused N-terminally with HA-tagged BlaN and C-terminally with an His-tag for purification. 
Between BlaN and pUL50 a 17 aa glycin-serin (GS) spacer was inserted for ensuring flexible 
connection between the fusion partners. For control reasons a pUL53 non-binding mutant of 
pUL50 was cloned as a Bla fusion by the same way and was termed NUL50DM-His. It 
harboured the same features than NUL50-His besides lacking the aa 51-59 of pUL50 
essential for binding to pUL53. The pUL53 PCA construct (CUL53-His) contained the 
variable and the conserved region 1 of pUL53 (aa1-129) which were fused N-terminally with 
HA-tagged BlaC and the spacer and C-terminally with a His-tag. All constructs were cloned 
into the pET24b (+) expression vector carrying a T7 promotor and kanamycin as selection 
marker.  
 
When CUL53-His is mixed in the assay with NUL50-His, protein-protein interaction leads to 
proximity of the Bla fragments and therefore reconstitution of Bla activity, which can be 
detected by hydrolysis of nitrocefin (see Figure 7B, Schnee et al., 2012). The construct 
NUL50DM-His lacks the binding site for pUL53, therefore mixing of NUL50DM-His and 
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CUL53-His does not result in Bla complementation and thus defines the background of 
nitrocefin hydrolysis. In presence of an inhibitor for the pUL50/pUL53 interaction, Bla 
fragments of NUL50-His and CUL53-His can not properly complement in the assay, resulting 
in a reduced nitrocefin hydrolysis rate. 
 
   
 
4.1.1 Propagation and purification of the Bla-tagged constructs 
Chemocompetent E. coli BL21-CodonPlus (DE3)-RIL were transformed with plasmids coding 
for the Bla-tagged NEC proteins. After overnight induction of expression by IPTG, the 
cultures were harvested and proteins were further purified by His-affinity chromatography 
(see chapter 3.7.3. for details). The bacterial lysates were applied on Ni2+-NTA columns, 
washed, and the proteins were eluted in three consecutive steps using 0.5 ml lysis buffer 
containing 250 mM imidazole. The eluates were collected separately (e1, e2, e3). To test the 
fractions for the presence of the NEC fusion proteins, 10 µl of each elutions were separated 
by SDS-PAGE and further analyzed by Coomassie staining and Western Blot analysis.  
Coomassie stained gels (Figure 8A) showed presence of large amounts of contaminating 
proteins, which made it difficult to assign the specific protein band. This E. coli derived 
impurity was previously described and had no consequences on specificity and background 
of the assay (Schnee et al., 2012). 
In order to assess the relative quantities of the expressed proteins, we used HA-specific 
Western Blot analysis. With this method all Bla-tagged proteins were detected at their 
Figure 7: The in vitro NEC-PCA. 
(A) Schematic representation of the in vitro 
NEC-PCA constructs. The HA-tagged BlaN 
was fused to the first 172 aa of pUL50 
separated by a glycine/serine spacer (S) 
resulting in NUL50-His. As negative control a 
BlaN fusion of pUL50 (NUL50DM-His) was 
constructed, lacking aa 51-59 of pUL50 
representing the binding site to pUL53. The 
HA-tagged BlaC and the spacer were fused 
to a pUL53 fragment containing the first 129 
aa of pUL53 (CUL53-His). All constructs 
carried a C-terminal His-tag for affinity 
purification. 
(B) Principle of the in vitro NEC-PCA. Upper 
row: Reconstitution of Bla activity when 
CUL53-His (53) is mixed with NUL50-His 
(50). Middle row: CUL53-His and NUL50DM-
His (50DM) do not interact due to the 
deletion of the pUL50-pUL53 interaction site. 
No complementation of the two Bla 
fragments. (C) Presence of an inhibitor 
(green) of the pUL50/pUL53 interaction 
competes Bla complementation when 
NUL50-His and CUL53-His are mixed. 
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predicted sizes of 28 kDa (CUL53-His), 42 kDa (NUL50-His) and 41 kDa (NUL50DM-His) in 
all three elution fractions (Figure 8B). Therefore eluted fractions were pooled and total 
protein concentrations were determined by the Bradford method. The pooled CUL53-His 
elutions constantly led to a total yield of around 1.5 mg protein, while pooled elutions from 
NUL50-His or NUL50DM-His reproducibly resulted in 7 mg total protein, respectively. 
 
 
4.1.2 Standardization of the assay 
To use the in vitro NEC-PCA for screening in a chemical compound library, the assay 
needed to be standardized. It was essential to provide constant and reproducible conditions 
for the reactions in all screening phases. Furthermore, it was important to determine the 
optimum capacity (minimal concentration of Bla-tagged proteins in the assay) and to 
determine an adequate time frame (assay reaction time). Finally, the real-time assay had to 
be transformed into an endpoint assay enabling multi-plate screening. A counter-screen had 
to be established to exclude irrelevant inhibitors of the reporter enzyme β-lactamase. 
 
4.1.2.1 Setting up the minimal essential protein concentrations 
To optimize the number of possible reactions derived from one protein purification, the 
minimal concentration of Bla-tagged proteins was determined which is minimally required to 
deliver specific signal for the interaction. Therefore, same parts of NUL50-His (3.3 µg /µl in 
25% glycerole) and CUL53-His (0.6 µg /µl in 25% glycerole) or NUL50DM-His (3.3 µg /µl in 
25% glycerole) and CUL53-His (0.6 µg /µl in 25% glycerole), respectively, were premixed 
(corresponding to dilution 1:1 in Figure 9). The above described ratio of NUL50-His and 
Figure 8: Bacterial 
expression of the Bla-tagged 
NEC proteins.  
(A) Coomassie stained SDS-
PAGE with three consecutive 
elutions (e1, e2, e3) from Ni2+-
NTA purifications of CUL53-
His, NUL-His and NUL50DM-
His, respectively. 10 µl of each 
elution was loaded onto a 12 
% SDS gel. Numbers on the 
right indicate marker bands (in 
kDa). (B) HA-specific Western 
Blots of the protein elutions of 
CUL53-His, NUL-His and 
NUL50DM-His. 10 µl of each 
elution was loaded onto a 12 
% SDS gel. Numbers on the 
right indicate marker bands (in 
kDa). 
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CUL53-His eluates (5:1) was established by testing for the highest activity using a setup, in 
which both components were applied in different amounts and was already described in 
(Schnee et al., 2012). Serial dilutions of the premixes were prepared using Na-phosphate 
buffer (pH 7.0). 40 µl of each dilution was then tested in a nitrocefin assay for Bla-activity. 
Furthermore, the reaction time was measured for each dilution of the NUL50-His/CUL53-His 
combination, which corresponded to the time until nitrocefin turnover reached the plateau 
phase. 
  
Figure 9: Standardization of the concentration of the Bla-tagged proteins for high-troughput 
screening (HTS). 
NUL50-His (3.3 µg /µl) and CUL53-His (0.6 µg /µl) or NUL50DM-His (3.3 µg /µl) and CUL53-His (0.6 
µg /µl), respectively, were premixed (1:1) and diluted to different concentrations with Na-phosphate 
buffer (pH 7.0). 40 µl of each dilution was then tested in nitrocefin assay (see 3.8.2) for Bla activity. 
Shown are means of at least 4 independent experiments. Error bars indicate the standard deviation. 
Numbers at the bottom indicate the time (in min) until the nitrocefin hydrolysis reached its plateau 
phase. 
 
As expected the signal of NUL50-His/CUL53-His mixtures decreased according to dilution 
(Figure 9). The NUL50DM-His/CUL53-His mixtures which defined the background activity of 
each corresponding NUL50-His/CUL53-His mixture showed low Bla activity in the 1:1 to 1:3 
dilutions, whereas in higher dilutions no activity could be determined (n.d.) anymore. This 
defined the signal for the NUL50-His/CUL53-His mixtures in all tested dilutions as specific 
and theoretically applicable for the library screen. The reaction time of the higher NUL50-
His/CUL53-His dilutions (1:12 and 1:16) was over 1 h. In addition, although hydrolysis curves 
in these dilutions reached a plateau, nitrocefin turnover did not reach 100% (not shown). This 
indicated that the PCA components started to turn inactive during the prolonged incubation 
period. Therefore, the Bla-tagged proteins were used in a 1:8 dilution in the screens 
corresponding to 16.5 µg total protein per well for the NUL50-His preparation and 3 µg for the 
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CUL53-His, respectively. This protein density corresponded to a hydrolysis rate of around 20 
milliabsorption units/min and a reaction time of 40 min. 
Based on this, fermentation of 2.5 l volume for each Bla-tagged protein was sufficient to 
perform more than 400 single assays. 
 
4.1.2.2 DMSO sensitivity of the assay 
The chemical compounds from EMC microcollections (Tübingen) were provided prespotted 
in 96-well plates and were reconstituted in the standard solvent DMSO for 30 min before the 
PCA was performed. Therefore the influence of DMSO on the PCA was determined implying 
the maximum tolerable concentration. To this end, the in vitro NEC-PCA was performed with 
the standardized protein amounts and activity (see previous chapter) in presence of different 
concentrations of DMSO (Figure 10). 
 
 
The Bla activity decreased only slightly in presence of 2.5% and 5% of DMSO, compared to 
the 0% control, whereas a strong decrease could be detected in higher concentrations  
(7.5% and 10%). Therefore, the standardized DMSO concentration was set to 5% in the 
library screen. 
 
4.1.2.3 Minimal concentration of potassium clavulanate as stop solution 
Larger screening trials using the in vitro NEC-PCA system demanded an endpoint 
measurement as final readout. To afford comparable conditions in all tested plates, the 
reaction should be stopped when the uninfluenced control reaction reached its plateau (40 
min reaction time (see chapter 4.1.2.1)). As stop solution, a commercial available β-
lactamase inhibitor was tested. In order to determine the minimal concentration of this 
inhibitor which is necessary to stop the reaction, different concentrations of potassium 
Figure 10: DMSO sensitivity 
of the in vitro NEC-PCA.  
The in vitro NEC-PCA was 
performed with standardized 
protein concentrations (see 
previous chapter) in presence 
of different concentrations of 
DMSO. Nitrocefin hydrolysis 
rate was determined at 495 
nm. Shown are means of 4 
independent experiments. 
Error bars indicate the 
standard deviation. 
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clavulante (Sigma) were applied to the standardized in vitro NEC-PCA and the nitrocefin 
turnover (absorption at 495 nm) was measured after 5 and 10 minutes and after 24h.  
 
Figure 11: Potassium clavulanate as stop solution in the in vitro NEC-PCA.  
The in vitro NEC-PCA was performed with standardized values. After 20 min of reaction, 10 µl 
potassium clavulanate solution (Sigma-Aldrich) was added at different concentrations to the 200 µl 
reaction mixture and absorption at 495 nm was measured immediately after adding (t=0, black bars) 
and after another 5 min (t=5 min, striped bars) and 10 min (t=10 min, dark gray bars) of incubation at 
37 °C. Additionally, the reaction was incubated at 4°C for further 24 h (t=24 h, gray bars) before 
absorption at 495 nm was measured again. Designations refer to end concentrations of potassium 
clavulanate after adding to the reaction. 
 
Compared to the mock-control (0 µM) in which the nitrocefin hydrolysis proceeded 
exponentially, in all tested concentrations of potassium clavulanate the hydrolysis was 
inhibited, resulting in reduced hydrolysis rates at 5 min after administration (Figure 11). 
However, the hydrolysis was not stopped completely at any applied concentration indicating 
a time delay which needed to be considered for the assay setup. This could be observed by 
comparing the values of 5 min to 10 min after potassium clavulanate administration. In 
contrast to the small but measurable increase between 0 and 5 min, no further increase of 
absorption at 495 nm could be measured between 5 to 10 min in concentrations from 100 µM 
to 1 µM. In the lowest applied concentration a slight increase was still visible. The samples 
were measured again after 24 h incubation at 4 °C. As expected, all nitrocefin is hydrolyzed 
in the mock sample, in the 100 µM to 1 µM samples the absorption increased slightly to the 
10 min values reflecting the natural decomposition rate of nitrocefin. The signal in the lowest 
test concentration increased less than the mock control but a residual Bla activity was 
evident. 
Thus, potassium clavulanate at 1 µM end-concentration was used to stop the in vitro NEC-
PCA for endpoint measurement in the high-throughput screen. 
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4.1.3 Optimal β-lactamase concentration for HTS counter-screen  
Candidate compounds arising from the HTS screen with in vitro NEC-PCA need to be tested 
for Bla inhibitory activity to exclude compounds affecting the reporter enzyme. Therefore, the 
compounds were tested in a counter-screen with β-lactamase exhibiting the same activity as 
the fusion proteins in the unaffected in vitro NEC-PCA.  
To this end, different concentrations of TEM-1 β-lactamase (Abcam) were tested for their 
nitrocefin hydrolysis activity to find the optimal matching enzyme concentration (Figure 12). 
 
 
Figure 12: Nitrocefin hydrolysis rate of TEM-1 β-lactamase.  
10 µl of different concentrations of TEM-1 β-lactamase (Sigma-Aldrich) were mixed with nitrocefin and 
Na-phosphate buffer (see Methods 3.8.3) and hydrolysis rate was determined at 495 nm. Designations 
refer to end concentrations of TEM-1 β-lactamase in the experiment. Shown are means of triplicates. 
Error bars indicate the standard deviation. 
 
0.25 µg/ml TEM-1 β-lactamase showed a hydrolysis rate of around 20 milliabsorption 
units/min which is in accordance with the standardized hydrolysis rate of the in vitro NEC-
PCA (chapter 4.1.2.1). Therefore, this enzyme concentration was used in the counter-screen 
to test the primary candidate compounds for direct reporter-inhibitory activity. 
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4.2 The pUL94/pUL99 interaction as potential drug target 
We could recently show that our cell-free NEC-PCA (in vitro NEC-PCA) was feasible to 
identify inhibitory peptides for the pUL50/pUL53 protein interaction (Schnee et al., 2012) and 
that it is suitable to be used in high-throughput screening approaches in small chemical 
compound libraries (this work). Next, the Bla based PCA system was tested on another 
essential viral protein-protein interaction to show that our approach is generally applicable.  
The herpesviral replication cycle offers a broad spectrum of viral protein-protein interactions. 
The perinuclear enveloped particles which are formed by budding through inner nuclear 
membranes (primary envelopment) fuse in a subsequent morphogenesis step with outer 
nuclear membranes. Unenveloped capsids in the cytoplasm are decorated with tegument 
proteins and then undergo secondary envelopment by budding into trans-Golgi network 
membranes, producing infectious particles that are secreted from cells (reviewed in (Johnson 
and Baines, 2011)). Two conserved viral proteins belonging to the pUL16 and pUL11 protein 
families of herpesviruses were shown to play a crucial role during this process of secondary 
envelopment. The HCMV representatives pUL94 and pUL99 were shown to interact at the 
site of capsid budding forming the secondary envelopment complex (SEC) (also see 1.3.2.2). 
The interaction between the pUL94 and the pUL99 HCMV protein was shown to be essential 
in viral replication (Phillips et al., 2012), not involved in DNA replication and independent of 
other viral proteins. Furthermore the linear binding site on pUL99 and non-binding mutants 
for pUL94 and homologs were already described (Liu et al., 2009; Liu et al., 2012; Maninger 
et al., 2011). Due to these properties this interaction was an interesting candidate to 
establish in the PCA system. Similar to the approach taken for the NEC core interaction, first, 
a cell-based PCA was established on the MCMV homologs pM94/pM99 based on 
information on their native interaction (Maninger et al., 2011). The homologous proteins of 
MCMV and HCMV are highly conserved and therefore should behave similarly in the same 
assay since a characterized non-binding small insertion mutant of pM94 was already 
described and here can be used to develop controls. Based on the observations on the 
MCMV proteins a cell-based PCA for the pUL94/pUL99 should be tested. Finally, on the 
basis of the results of the previous steps, the fusion proteins of the HCMV homologs should 
be transferred into the bacterial expression system to make the SEC-PCA cell-free and HTS-
compatible. 
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4.2.1 Gateway® compatible Bla-fragment fusion vectors 
To construct the new Bla fusion proteins, Gateway® (Invitrogen) compatible fusion plasmids 
(pEF5/FRT-V5-Nf-DEST and pEF5/FRT-V5-Cf-DEST, see Materials and Methods) were 
constructed allowing an N-terminal fusion of genes with the Bla fragments for cell-based 
PCAs in a one-step LR reaction. This platform would allow to integrate other viral interactions 
into the cell-based PCA system since many herpesvirus ORF libraries including CMV sets 
existing in Gateway® compatible entry plasmids and have been used for other interaction 
screens (Fossum et al., 2009; Vizoso Pinto et al., 2011). The general cloning approach is 
depicted in Figure 13. 
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Figure 13: Schematic representation of the Gateway
®
 compatible Bla fusion plasmids. The HA-
tagged BlaN (right) and BlaC (left) sequences and a Glycine-Serine spacer sequence (S) were cloned 
into the Gateway® expression vector pEF/FRT-V5-DEST between promotor (pef-1) and recombination 
site (attR). CMV gene entry clones with attL recombination sites were recombined with the Bla fusion 
plasmids in a LR reaction resulting in a plasmid expressing N-terminal Bla fragment tagged CMV 
proteins. 
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4.2.2 The pM94/pM99 interaction in the PCA 
4.2.2.1 Signal and background of the MCMV SEC-PCA 
The M94 gene was fused to the BlaN fragment via the Gateway® compatible fusion vector 
pEF5/FRT-V5-Nf-DEST and M99 was fused pEF5/FRT-V5-Cf-DEST to the BlaC fragment. 
Next, both gene fusions were sub-cloned in a pO6T vector backbone resulting in pO6T-Nf-
M94 and pO6T-BlaCf-M99 to generate expression vectors for the cell-based PCA. To 
determine the background signal of the PCA, the BlaN fragment was fused to a mutant of 
pM94 (pO6T-Nf-M94i13) which is deficient in binding pM99 (Maninger et al., 2011). 
As further control the genes M53 and M50 and a non-binding mutant of M50 were fused to 
the Bla fragments by the Gateway® fusion vectors (pO6T-Cf-M53, pO6T-Nf-M50 and pO6T-
Nf-M50DM). The interaction of these proteins was already characterized by PCA (Schnee et 
al., 2006) and served as confirmation for the Gateway® fusion system in which the linker 
between the viral proteins and the Bla fragment had to be modified to fit in the recombination 
sites. 
To test the SEC proteins in PCA, the expression vector pO6T-BlaCf-M99 was co-transfected 
into 293T cells with either pO6T-Nf-M94 or pO6T-BlaNf-M94i13. Furthermore, 293T were 
transfected with the individual SEC constructs. 24 h after transfection the cells were 
harvested and lysed. Nitrocefin was added to the cell lysates and the hydrolysis rate was 
determined by a kinetic readout over 30 min, measuring the absorption at 495 nm every 9 
seconds (Figure 14A). For the control interaction, co-expression of N-M50 and C-M53 
resulted in hydrolysis rate of around 35 while co-expression of the non-binding mutant N-
M50DM with C-M53 resulted in a more than 10 fold lower signal confirming the Gateway 
derived fusion proteins to be functional also in the PCA. 
 
For the SEC proteins, co-expression of N-M94 and C-M99 led to a hydrolysis rate of around 
70, which was more than 20 fold higher than in the lysates of the co-expression of non-
binding N-M94i13 with C-M99 or of single expressions. To ensure, that the low signal 
detected in the PCA with the non-binding M94 mutant was not due to poor protein 
expression, residual lysates of the co-expressions of the SEC constructs were denatured in 
total lysis buffer and used for Western Blot analysis probing with HA-specific antibody. The 
wildtype and the mutant construct of pM94 were detected at the predicted molecular weight 
of 62 kDA and expressed at the expected level (Figure 14B). 
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4.2.2.2 Specificity of the MCMV SEC-PCA 
After the establishment of the SEC-PCA in cells the specificity of the assay was tested in the 
presence of increasing amounts of M99-Flag, which binds N-M94 but does not complement 
due to the lack of the complementary Bla fragment. If the PCA is dependent on the 
pM94/pM99 interaction Flag-tagged pM99 would compete with C-M99 for binding, which then 
should result in the decrease of the PCA signal. Therefore, M99-Flag was expressed by the 
expression construct pOriR6K-M99FLAG (Maninger et al., 2011). The competitor pOriR6K-
M99FLAG was added to the co-transfection mixture (3 µg pO6T-Nf-M94 and 3 µg pO6T-
BlaCf-M99) in increasing amounts from 0.5 µg to 2 µg. Transfections mixtures were adjusted 
to a total amount of DNA of 8 µg by an adequate addition of carrier DNA pOriR6K-zeo-ie. As 
shown in Figure 15A, the PCA signal decreased in a M99-Flag concentration dependant 
manner. The initial hydrolysis rate of 37 milliabsorption units/min gradually reduced in 
presence of increasing amounts of M99-Flag by a third reflecting the relative proportion of 
Bla-tagged and non-Bla-tagged M99 in the assay. The amounts of N-M94, C-M99 and M99-
Flag in the assay were visualized by Western Blots probed for HA- or Flag-tag, respectively 
(Figure 15B). All proteins were detected at the predicted sizes of 62 kDa (N-M94), 27 kDa 
(C-M99) and 12 kDa (M99-Flag). Protein amounts of N-M94 and C-M99 were constant in all 
A 
B 
Figure 14: Establishment of the 
SEC-PCA for MCMV. (A) Bla activity 
in 293T cell lysates after co- and 
individual expressions of the 
Gateway® derived Bla fusion 
constructs. C-M53 was co-expressed 
with N-M50 or N-M50DM, 
respectively. C-M99 was co-
expressed with N-M94 or N-M94i13, 
respectively. Furthermore N-M94, N-
M94i13 and C-M99 were single 
expressed. 24 h post transfection 
cells were lysed and nitrocefin was 
added. Mean hydrolysis rates were 
determined and shown as rate in 
milliabsorption units/min. Shown are 
means of at least 4 independent 
experiments. Error bars indicate the 
standard deviation. (B) Expression 
levels of N-M94 and N-M94i13 in co-
transfection with C-M99 detected by 
anti-HA specific Western Blot 
analysis. Numbers on the right 
indicate the protein marker in kDa. 
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samples while a continuous increase of M99-Flag protein amount could be detected relative 
to transfected pOriR6K-M99FLAG. 
 
 
Figure 15: Specificity of the MCMV SEC-PCA. (A) Competition assay. Bla activity in cell lysates 
after co-expression in 293T cells. N-M94 and C-M99 (3 µg of each DNA) were co-expressed together 
with increasing amounts of M99-Flag. Total DNA amounts in transfections were kept constant at 8 µg 
by addition of carrier DNA. Mean hydrolysis rates were determined and shown as rate in 
milliabsorption units/min. Shown are means of triplicates. Error bars indicate the standard deviation. 
(B) Protein levels of N-M94, C-M99 and M99-Flag in the competition assay. N-M94 and C-M99 were 
detected by HA-specific antibody, M99-Flag by Flag-specific antibody. Sizes of the marker bands in 
kDa are indicated on the left. 
 
4.2.3 pUL94 and pUL99 in the PCA 
4.2.3.1 Cell-based SEC-PCA of HCMV 
Because the interaction of the MCMV proteins pM94 and pM99 could be monitored by cell-
based PCA there was interest to establish a HTS approach for inhibitors of the homologous 
interaction in HCMV. pUL94 and pUL99 were, therefore, tagged with Bla fragments by the 
Gateway® compatible Bla fusion plasmids as described in 4.2.1 and were subsequently sub-
cloned in the pO6T vector backbone for expression. This resulted in plasmids (pO6T-Nf-
UL94 and pO6T-Cf-UL99) expressing BlaN-tagged pUL94 (NUL94) and BlaC-tagged 
(CUL99). To determine the background signal of the PCA, pUL99 mutant lacking the amino 
acids 22-43 was BlaC-tagged (CUL99del). These amino acids were shown to be crucial in 
binding pUL94 by previous FRET analysis (Lui et al., 2009).  
When NUL94 and CUL99 were co-expressed, the hydrolysis rate of nitrocefin in the cell 
lysates was around 90 times higher than in cells which expressed NUL94, CUL99 and 
CUL99del alone. The hydrolysis rate detected after co-expression of NUL94 and CUL99del 
was around 20% and defined the background of the PCA (Figure 16A). Protein expression 
levels from co-expression lysates were checked by an anti-HA specific Western Blot. All 
constructs were detected at their expected molecular weights (NUL94: 62 kDa; CUL99: 36 
A B 
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kDa; NUL99del: 34 kDa). CUL99 and CUL99del were expressed almost to the same level 
(Figure 16B). 
 
Figure 16: The cell-based SEC-PCA of HCMV. (A) Bla activity in 293T cell lysates after co- and 
individual expressions of the Gateway® derived Bla fusion constructs. NUL94 was co-expressed with 
CUL99 or CUL99del, respectively. Furthermore NUL94, CUL99 and CUL99del were single expressed. 
24 h post transfection cells were lysed and nitrocefin was added. Mean hydrolysis rates were 
determined and are shown as rate in milliabsorption units/min. Shown are means of triplicates. Error 
bars indicate the standard deviation. (B) Expression levels of CUL99 or CUL99del (stars) in co-
transfection with NUL94 detected by anti-HA specific Western Blot analysis. Numbers on the left 
indicate the protein marker in kDa. 
 
4.2.3.2 Cross-complementation between the UL16 family members of MCMV and 
HCMV 
There is only little structural information about pUL94 available to date. Soly for its MCMV 
homolog, pM94, it was previously shown that a small insertion mutation can completely 
abolish binding to pM99, the homolog of pUL99 (Maninger et al., 2011), indicating a limited 
interaction site and therefore a potential for small molecules to interfere. The alignment of 
pUL94 and pM94 (Figure 17B) showed a high sequence homology (48.4% consensus 
positions, 32.6% identity positions). Therefore it was interesting whether the pM94 can bind 
to the partner of pUL94, pUL99. Appropriate Bla fusion proteins of both viruses in 
heterologous pairs were co-expressed to determine their ability to cross-complement in the 
PCA (Figure 17A). 
Co-expression of CUL99 with N-M94 resulted in a 100 times higher nitrocefin hydrolysis rate 
than co-expression with N-M94i13 and a 10 times higher rate than co-expression of 
CUL99del with N-M94, indicating that binding site is conserved between the MCMV and 
HCMV proteins of the pUL16 family. 
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Figure 17: Binding site conservation between pM94 and pUL94. (A) Nitrocefin hydrolysis rates of 
lysates from homologous and heterologous co-expressions of MCMV and HCMV Bla fusion proteins of 
the UL16 and UL11 protein families. NUL94 was homologously co-expressed with CUL99 or non-
binding mutant CUL99del (light grey bars). N-M94 or N-M94i13 was homologously co-expressed with 
C-M99 (dark grey bars) and heterologously co-expressed with NUL99 (striped bars). Furthermore N-
M94 was heterologously co-expressed with NUL99del (striped bar). Mean nitrocefin hydrolysis rates 
from lysates were determined at least 4 independent experiments and shown as rate in milliabsorption 
units/min. Error bars indicate the standard deviation. (B) Sequence alignment of pUL94 and pM94. 
Yellow indicates identical, green similar residues. 
 
4.2.3.3 Bla-complementation by combined single expression lysates of SEC-proteins 
The major interest was to establish a PCA which can be used for high-throughput screening 
of inhibitory molecules for the pUL94/pUL99 interaction. According to the previously 
established cell-free NEC-PCA (Schnee et al., 2012) in which the complementing fusion 
proteins were separately expressed, I tested if NUL94 and CUL99 could complement when 
expressed upon separate transfection and just combined after cell lysis. Therefore, NUL94 
and CUL99 were separately expressed in 293T, lysates were prepared and combined in the 
nitrocefin assay. To verify the background, NUL94 lysates were combined with lysates of 
single expressed non-binding CUL99del. Furthermore, each construct was combined with 
lysates of mock-transfected 293T. 
Combined lysates of NUL94 and CUL99 resulted in at least 20 times higher nitrocefin 
hydrolysis rate than the reaction containing non-binding fragments or mock-combinations 
(Figure 18A). Comparable protein amounts in the lysates and equality of expression in case 
of CUL99 and CUL99del were verified by HA-specific Western blot (Figue 18B). Remarkably, 
the SEC-PCA with the combined lysates exhibited 4 times less background compared to the 
co-expression based SEC-PCA in 4.2.3.1. This background improvement might be a result of 
reduced spontaneous unspecific β-lactamase folding by the shortened time of encountering 
of the Bla-tagged proteins under such conditions. 
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4.2.3.4 The bacterial expression constructs of the SEC-PCA 
High-throughput screens demand for simple approaches which can be performed in a cost-
effective way. The previous experiment showed that NUL94 and CUL99 can complement 
when the proteins were expressed separately in 293T and lysates were combined in for PCA 
assay. In accordance to the cell-free NEC-PCA (Schnee et al., 2012) which uses constructs 
derived from bacterial expression, the components of a SEC-PCA were produced in E.coli. 
Therefore, full-length pUL99 was fused N-terminally with the HA-tagged BlaC and Glycine-
Serine spacer and C-terminal with a His-tag for later purification (CUL99-His, Figure 19). As 
negative control, the pUL99 mutant lacking the 22 amino acids responsible for binding to 
pUL94 was constructed in a similar way (CUL99del-His). Full-length pUL94 was fused N-
terminally to the HA-tagged BlaN fragment and a Glycine-Serine spacer and C-terminally 
with a His-tag (NUL94-His). All constructs were cloned into pET24 b (+)-expression vector 
background under T7 promotor. 
Figure 18: Bla-complementation of 
combined single expression 
lysates of SEC-PCA proteins.  
(A) NUL94, CUL99 and CUL99del 
were single expressed in 293T cells. 
Cells were harvested and cell lysates 
were prepared as described in 3.8.1 
for cell-based PCA. 25 µl of the 
indicated lysates were tested in 
combination with each other or with 
25 µl of lysates from untreated 293T 
cells for reconstituted Bla activity. 
Mean nitrocefin hydrolysis rates were 
determined in 4 independent 
experiments and shown as rate in 
milliabsorption units/min. Error bars 
indicate the standard deviation.  
(B) HA-specific Western Blot 
analysis of lysates of single 
expressions of NUL94, CUL99 and 
CUL99del in 293T. Sizes of the 
marker bands in kDa are indicated 
on the left. 
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Figure 19: Schematic representation of the in vitro SEC-PCA constructs of HCMV. The HA-
tagged BlaC was fused to full length pUL99 separated by a glycine/serine spacer (S) resulting in 
CUL99-His. As negative control a BlaC fusion of pUL99 (CUL99del-His) was constructed, lacking aa 
22-43 of pUL99 representing the binding site to pUL94. The HA-tagged BlaN and the spacer were 
fused to full length pUL94 resulting in NUL94-His. All constructs carried a C-terminal His-tag for affinity 
purification. 
 
4.2.3.4.1 Purification of Bla-tagged SEC proteins from bacteria 
The Bla-tagged SEC-proteins were expressed in BL21-CodonPlus (DE3)-RIL and further 
processed as described in 3.7.1. Bacterial cultures (2.5 l) were lysed by sonification (3.7.2) 
and applied to Ni2+-affinity purification for the recombinant proteins (3.7.3). Protein elutions 
(1.5 ml) were analyzed by Coomassie-stained SDS-PAGE and HA-specific Western blot for 
purity and protein amounts. 
The protein concentration derived from elutions of NUL94-His was about in 2 mg/ml. For the 
deletion mutant CUL99del-His, the protein yield was around 2 times higher (1.7 mg/ml) than 
that of the wildtype version CUL99-His (0.8 mg/ml). The Coomassie stained gels showed 
beside the specific bands for all three recombinant proteins several impurities (Figure 20A). 
Thereby, contamination of CUL99del-His appeared stronger than of CUL99-His. In the HA-
specific Western Blot (Figure 20B), pUL99 constructs were detected at their predicted sizes 
of 34 kDa (CUL99-His) and 32 kDa (CUL99del-His) in equal amounts, confirming that the 
difference in protein yields resulted from larger background impurities in CUL99-His elutions. 
NUL94-His, which was expected at a size of 61 kDa on the Western blot, was detected as a 
smear between sizes of 50 to 70 kDa, which might reflect some protein degradation. 
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Figure 20: Bacterial expression of Bla-tagged SEC proteins of HCMV. (A) Coomassie stained 
SDS-PAGE with samples after Ni2+-NTA purification from the expressed CUL99-His, CUL99del-His 
and NUL94-His. 10 µl of the elutions were loaded on a 12% SDS gel. Black stars mark the positions of 
the recombinant proteins. Sizes of the marker in kDa are indicated on the left. (B) Western Blot 
analysis of the protein elutions from CUL99-His, CUL99del-His and NUL94-His. 10 µl of each protein 
elution was separated by SDS-PAGE, blotted and immunodetected with anti-HA specific antibody. 
Sizes of the marker in kDa are indicated on the right. 
 
4.2.3.4.2 Bla complementation of prokaryotic expressed fusion proteins 
In order to determine whether the bacterial derived Bla-tagged fusion proteins could replace 
eukaryotic expressed in the SEC-PCA, they were tested for Bla complementation in a 
nitrocefin assay. Therefore, 25 µl of the NUL94 elution were combined with 25 µl of the 
CUL99-His or CUL99del-His elution, respectively. Furthermore, 25 µl of 293T lysates 
expressing NUL94, CUL99 or CUL99del were combined with the respective bacterial elutions 
or with another and nitrocefin hydrolysis was determined (Figure 21). 
Combinations including bacterial derived NUL94-His showed no significant difference in 
nitrocefin hydrolysis when using corresponding fragments for positive and negative binding. 
However, eukaryotic derived NUL94 could complement with eukaryotic (CUL99) confirming 
the results described the previous chapter. Interestingly, the BlaC-tagged pUL99 (CUL99-
His) derived from prokaryotic expression, showed a significant complementation compared to 
the non-binding pUL99 controls (CUL99del or CUL99del-His, respectively) when it was 
combined with NUL94 expressed in eukaryotic cells. 
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Figure 21: Bla complementation of recombinant expressed SEC-PCA proteins. Bla activity after 
combing eukaryotic (eu) and prokaryotic (p) expressed SEC-PCA proteins. 25 µl of a lysat from 293T 
cells expressing NUL94 or 25 µl of NUL94-His elution were combined with 25 µl of lysates or elutions 
of CUL99 (+eu), CUL99-His (+p), CUL99del (-eu) and CUL99del-His (-p), respectively. Mean nitrocefin 
hydrolysis rates were determined in at least 5 independent experiments and shown as rate in 
milliabsorption units/min. Error bars indicate the standard deviation. Significance (*) was calculated by 
student’s t test (p<0.002). 
 
These data showed that the PCA approach developed for characterization of the core 
interaction of the NEC proteins can be transferred to other essential viral protein interactions. 
* 
* 
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4.3 HTS of a compound library 
The HTS to identify inhibitors of the pUL50/pUL53 core interaction was performed with the 
standardized conditions for the in vitro NEC-PCA (iPCA) and the beta-lactamase counter-
screen as described in chapter 4.1.2. 
 
Briefly, preplated compounds were reconstituted in 10 µl DMSO for 30 min, before the iPCA 
was peformed in a total volume of 200 µl with fixed amounts of NUL50-His and CUL53-His 
proteins (4.1.2.1). The reaction was stopped after 40 min of incubation at 37 °C by addition of 
potassium clavulante and nitrocefin turnover was determined by absorption measurement at 
495 nm. Inhibitory compounds from the iPCA were re-tested in a nitrocefin hydrolysis assay 
with added β-lactamase exhibiting the same activity as the Bla in the iPCA to exclude direct 
inhibitors of the reporter enzyme. 
 
4,000 structurally highly diverse potentially non-toxic compounds with pharmacological 
properties were selected from a small-molecule library containing 30,000 individual 
heterocyclic structures (Bauer et al., 2011). This library has been already tested for toxicity in 
different mammalian cell lines (Caco-2, HeLa, A549 and A431) (Bauer et al., 2011) therefore 
rational selection against highly toxic compounds was possible. This pre-selected library was 
provided by EMC microcollections (Tübingen). Non-toxic known beta-lactamase inhibitors, 
however, were not filtered out and provided an internal control in all stages of the subsequent 
screening. To increase cost- and time-effectiveness, major parts of the library were plated in 
a first screening round in a compressed format consisting of combinations of 5 compounds 
per well and different concentrations in 6 different structural groups (Screening scheme is 
shown in Figure 22A). From this pre-screening results 4,000 compounds were selected for a 
second screening round of single compounds per well in fixed concentration (10 µM, Figure 
22B).  
 
In both screening phases the iPCA was performed in 96-well format. Thereby, 80 wells on 
each plate were filled with compounds dissolved in 10 µl DMSO, in 14 wells the control 
reaction was performed (in presence of 10 µl DMSO) and 2 wells harboured potassium 
clavulanate to reflect total inhibition of the reaction. For evaluation, the absorption at 495 nm 
in the compound wells (mean values of duplicates in the second phase of screening) was set 
relative to the mean value of absorption at 495 nm of the 14 control reactions (100%) on the 
corresponding plate.  
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99 compounds were identified that displayed >33% signal reduction (Figure 13B). Total 
inhibition of the reaction by potassium clavulanate resulted in ~80% signal reduction (data 
not shown). Compounds were tested further in a counter-screen for direct effects on the β-
lactamase reporter. 97 compounds showed inhibitory effects including also already known 
beta-lactamase inhibitors, which confirmed the reliability of the selection schedule. On the 
other hand, this test confirmed the specificity of two compounds which inhibited the iPCA but 
not the β-lactamase. Therefore, these two compounds were selected for further analysis of 
their effective inhibitory concentration on the pUL50/pUL53 interaction in the PCA. 
 
 
    
 
A 
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Figure 22: HTS of the in vitro NEC-PCA (iPCA) in the compound library. (A) Screening scheme. 
Compounds were screened in three consecutive phases in 96-well format. In the pre-screen phase, 
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compound mixes in three different concentrations (50 µM, 10 µM, 5 µM) were tested in duplicates in 
the iPCA for pre-selection. In the second phase, 4,000 single compounds in 10 µM concentration were 
tested in the iPCA. The 99 hits from the second phase were counter-screened for β-lactamase 
inhibition and an iPCA for verification, identifying finally 2 specific inhibitors. (-) indicates wells of the 
control reaction, (+) indicates wells containing potassium clavulanate (10 µM; 100% inhibition) to 
reflect total inhibition. (B) Scatter blots of the second phase single compound screen with iPCA. 
Numbers on the x-axis indicate column numbers. Each column reflects values of 8 compounds in the 
screen. Values are means of independent duplicates and are normalized to the control reaction 
(100%). 
 
4.3.1 IC50 determination of candidate compounds 
The chemical structures which were identified as inhibitors of the pUL50/pUL53 core 
interaction by the HTS are shown in Figure 23A. The two compounds, designated here as 
30E06 and 30E07, are structurally related and belong to the same chemical class. To 
determine IC50 values of the two compounds, Bla-activity was measured after application of 
different compound concentrations to the iPCA in relation to mock control (Figure 23B). 
Values were fitted into a dose-response curve by the program GraphPad Prism 4.0 and half 
inhibitory concentration (IC50) was calculated. The IC50 of 30E06 was 4.61 µM and the IC50 for 
the 30E07 was 10.29 µM, respectively.  
 
Figure 23: IC50 analysis of candidate inhibitors of the pUL50/pUL53 interaction. (A) Chemical 
structures of the candidate inhibitors designated 30E06 and 30E07 are indicated. (B) The 
standardized in vitro NEC-PCA (iPCA) was incubated with different concentrations (in µM) of 
candidate compounds 30E06 and 30E07 and Bla-activity was measured and set into relation of mock 
control (100% activity). Shown are means of duplicates. 
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In this experiment the half-inhibitory concentration of candidate compound 30E06 was about 
50% of that of candidate compound 30E07. This assay confirmed that the conditions used in 
the screen were well chosen and the detailed iPCA test confirmed the inhibitory potential of 
both compounds. 
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4.4 Characterization of the inhibitory effect of the HTS-hits in the biological 
context 
4.4.1 Influence of the HTS-hits on the viability of cultured cells 
In order to determine the maximal tolerated concentrations of the compounds 30E06 and 
30E07 applicable in further experiments, cytotoxicity assays were performed as described in 
3.5.4 testing primary MEF and HFF cells (Figure 24) and U2OS and 293T cell lines. The 
viabilities of the treated cells measured by their reducing potential were compared to the 
values observed on untreated cells on the corresponding day. As depicted in Figure 15, the 
30E06 was non-toxic on MEF and HFF cells up to a concentration of 25 µM, whereas in the 
highest tested concentration (100 µM) a significant drop of reducing potentials were detected 
on both cell types. Furthermore, 50 µM 30E06 had a similar effect on MEF cells. For 30E07 
differences to untreated cells were not found even in the highest tested concentration of 100 
µM either on MEF or HFF cells. The established cell lines we used grew continuously with 
one doubling a day. Therefore, we measured viability only at one time point spanning about 
three cell divisions. Since their significantly higher metabolic activity we also expected them 
to be more vulnerable in the viability assay as primary cells. Accordingly for the U2OS and 
293T cell lines, the toxicity was tested after 3 days post application of the compounds. 30E06 
was non-toxic on both cell lines only up to concentrations of 10 µM, while 30E07 was non-
toxic up to 50 µM concentration (data not shown). This data showed us that 30E07 can be 
used between in 50-100 µM concentration depending on whether the assay is carried out on 
primary cells or cell lines, whereas the 30E06 compound could only be used in primary cells 
up to a concentration of 25 µM.  
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Figure 24: Effects of candidate compounds on viability of primary fibroblasts. Different 
concentrations of compound 30E06 were incubated on MEF (A) or HFF (B) and cell proliferation was 
tested in a two day intervals by application of CellTiter96®Aqueous One Solution (Promega) and 1 h 
incubation at 37 °C. Same was done for candidate compound 30E07 (C and D). DMSO concentration 
was maintained to 1% in each well. Days (d) post compound application are shown on the x-axis and 
viability is given in % (normalized mean absorptions at 490 nm of cells with compound/ normalized 
mean absorptions at 490 nm of mock treated cells) on the y-axis.  
 
4.4.2. Inhibition of pUL50/pUL53 interaction in cell-based assays 
Next, HTS-hits were tested for their ability to disrupt the pUL50/pUL53 interaction in the 
cellular context. Due to its lower cellular toxicity the tests were performed using only 30E07. 
The minimal cell-toxic concentration of 30E06 was close to its half inhibitory concentration in 
the NEC-PCA, therefore this compound could not be tested in these assays because its 
specific effects could not be separated from unspecific toxicity. 
 
4.4.2.1 Candidate compound 30E07 inhibits in the cell-based NEC-PCA 
First, 30E07 was tested for its inhibitory potential in a cell-based NEC-PCA which was 
previously established in our lab (Schnee et al., 2006). In contrast to the cell-free NEC-PCA 
setting, constructs of the cell-based PCA setting involved the full-length versions of pUL53 
and pUL50 and are performed in 293T cells. BlaN-tagged pUL50 (NUL50) was co-expressed 
with BlaC-tagged pUL53 in 293T cells in absence (+DMSO) and presence of the 50 µM of 
30E07 (+30E07). 24 h post transfection Bla activity was determined by the rate of nitrocefin 
hydrolysis (see Figure 25A). For background determination, single expressions of both fusion 
proteins were included. 
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Background Bla activity in single expressions lysates was low (~4%). Bla activity in lysates 
from 30E07-treated cells was reduced to around 54% compared to mock-treated co-
expressions. In order to exclude signal reduction was due to decreased protein expression, 
lysates were analyzed by Western Blot specific to the HA-tag present in both fusion proteins 
(Figure 25B). Thereby, it was shown that expression of the PCA components were not 
reduced by the drug treatment, suggesting a direct inhibitory effect of 30E07 on protein-
protein interation in the cell-based NEC-PCA. On the other hand, these data also confirm the 
lack of unspecific toxicity after application of 30E07 at 50µM concentration for 293T cells. 
 
4.4.2.2 Candidate compound 30E07 abrogates co-localization of pUL50 and pUL53 in 
the nucleus 
The viral components of any studied NECs are co-localized at the nuclear rim after their co-
transfection (Dal Monte et al., 2002; Muranyi et al., 2002). If the core NEC interaction 
between the pUL50 and pUL53 (or their homologs) is hindered, the pUL53, as its all studied 
homologs, should de-localize to show a diffuse nucleosolic appearance (Dal Monte et al., 
2002; Lotzerich, Ruzsics, and Koszinowski, 2006). In order to determine, if candidate 
compound 30E07 effects co-localization of pUL50 and pUL53 in the cell, a confocal 
immnofluorescence analysis was performed. To this end, pUL50 with a C-terminal HA-tag 
(UL50HA) and pUL53 with an N-terminal Flag-tag (FlagUL53) were co-expressed in U2OS 
cells in presence and absence of 30E07. As controls, proteins were also expressed alone. 
Figure 25: Effect of 30E07 in cell-
based NEC-PCA. 
(A) Bla activity in cell lysates after 
single and co-expression in 293T. 
CUL53 and NUL50 were single and 
co-expressed in 293T. 6 h post 
transfection medium was exchanged 
in the co-expressions to medium 
containing 50 µM 30E07 (+30E07) or 
medium containing 0.5% DMSO 
(+DMSO) as control. After further 16 
h of expression, cells were lysed and 
Bla activity was determined by 
nitrocefin hydrolysis. Error bars 
indicate standard deviation. 
Significance (*) was determined by 
student’s t test (p<0.02). 
(B) Protein expression levels in the 
293T lysates. 5 µl of each lysate was 
separated by SDS-PAGE (12%), 
blotted and immunodetected by anti-
HA (upper blot) and anti-actin 
antibody (lower blot). 
Numbers on the left indicate the 
protein marker in kDa. 
* 
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After 24 h of incubation samples were stained for indirect immunofluorescence and the 
results are shown in Figure 26. 
Co-transfection experiments in absence of the candidate compound 30E07 (DMSO) showed 
the expected co-localization of both proteins at the nulear rim. However, co-expression of 
both proteins in presence of the candidate compound 30E07 showed homogenous 
distribution of pUL53 in the nucleus comparable to the result of pUL53 expression in 
isolation, while pUL50 still located at the nuclear rim.  
 
Figure 26: Effect of 30E07 on cellular localization of pUL53 and pUL50. U2OS cells were single 
(first two columns) or co-transfected with pOriR6K-Flag-UL53 and pOriR6K-UL50-HA on 8 well µ-
slides (Ibidi) with FuGene transfection reagent (Roche). 6 h post transfection DMSO (control) or 
candidate compound 30E07 was added. Cells were further incubated at 37 °C for 18 h before they 
were fixed and processed for immunofluorescence. Flag specific antibody was used to visualize Flag-
tagged pUL53, HA-specific antibody for HA-tagged pUL50. Cell nuclei were counterstained with TOP-
PRO 3. Scale bars indicate 10 µm. 
 
We therefore concluded that the compound - similar to the in vitro screen - also blocked the 
pUL50/pUL53 interaction in cells and in the nucleus. 
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4.4.3 Characterization of the antiviral activity of the screening hits 
4.4.3.1 30E06 and 30E07 show dose-dependent antiviral activity against HCMV 
To test the screening hits 30E06 and 30E07 for direct antiviral activity we utilised the HCMV-
Luc reporter assay (3.6.4). Here, the spread of a Luc expressing recombinant HCMV can be 
monitored by increase of the Luc expression over time (Scrivano et al., 2011). To this end, 
HFF cells were infected at a low MOI (0.01 pfu/cell for 1.5 h) with the HCMV reporter virus. 
The infected cultures were incubated up to 2-8 days with normal medium or medium 
containing different concentrations of 30E06 and 30E07. Cells were lysed at 2, 4, 6 and 8 
days after infection and luciferase activity of the cell extracts was determined by direct 
luminometery (Figure 27). 
 
 
Figure 27: Antiviral effects of 30E06 and 30E07 on HCMV reporter virus. HFF cells were infected 
with the HCMV reporter virus TB40-Luc expressing the firefly luciferase at an MOI of 0.01 pfu/cell and 
incubated with different concentrations of (A) 30E06 or (B) 30E07 for up to 8 days. Luciferase activity 
was determined every second day in cell lysates on a luminometer. Shown are means of triplicates. 
Numbers on the right indicate compound concentrations in µM. 
 
Lysates of non-treated infected HFF (0 in Figure 18 A and B) showed the expected increase 
of luciferase signal over the time. In contrast, no increase of infection induced luciferase 
activity was observed in the presence of either 30E06 (Figure 27A) or 30E07 (Figure 27B) at 
the highest non-toxic concentrations resembling a complete block of viral replication. 
Treatment with lower compound concentrations resulted in a dose-dependent decrease of 
the slope of the rising luciferase expression indicating dose-dependent limitation of virus 
spread. 
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4.4.3.2 30E06 and 30E07 reduce release of infectious virus into supernatants 
To verify the antiviral effect of the candidate compounds 30E06 and 30E07 observed in 
HCMV-Luc reporter assay both compounds were next tested in a plaque reduction assay. To 
this end, HFF were infected with TB40-BAC4 at an MOI of 0.2 pfu/cell and then treated with 
the compounds in the highest non-toxic concentrations or with 1% DMSO (mock). 
Supernatants of the infected cultures were collected distinct days post infection until day 8. 
The amount of released infectious virions was quantified by plaque assay after titration. 
Results are shown in Figure 28. As expected, viral titers in supernatants of mock-treated (1% 
DMSO) infected cells constantly increased over time of infection. Compared to that, around 
100 times less infectious virus could be detected in supernatants of 30E06 treated infected 
cells. Furthermore, no infectious virus could be found in supernatants from infected cells 
treated with 30E07 implying a complete block of viral replication.  
 
  
Figure 28: Growth characteristics of HCMV (TB40-BAC4) in presence of candidate compounds. 
HFF cells were infected with TB40-BAC4 at an MOI of 0.2 for 1.5 h and then treated with medium 
containing the highest non-toxic doses of 30E06 (final concentration: 25 µM) and 30E07 (final 
concentration: 100 µM) or DMSO (1%) as control. Supernatants were harvested at indicated days and 
viral titers were determined by TCID50 assay. 
 
Due to the more desirable toxicity profile of 30E07 (4.4.1), further studies on the lead 
compounds were performed with 30E07. 
4.4.3.3 30E07 moderately reduces expression of viral proteins 
To explore the mode of action of 30E07, effects on viral protein expression in general were 
determined. To this end, HFF cells were infected with HCMV-TB40-BAC4 at an MOI of 0.2. 
The infection was allowed to proceed in absence (-) and presence (+) of 100 µM 30E07 for 
24, 48, 72 and 96h. Infected cells were harvested and processed for Western blotting. Then, 
the presence of representative virus proteins expressed by immediate-early (IE), early (E) 
and late (L) kinetics were determined. As depicted in Figure 29, the levels of HCMV IE1 (IE), 
UL44 (E) and gB (L) proteins were analyzed. The levels of all three viral protein classes were 
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moderately reduced in the drug treated aliquots. Notably, the levels of IE1 proteins were  
affected only as late as 72h post infection. These results suggested that 30E07 affected 
mildly the viral gene expression in general. Alternatively mainly HCMV DNA replication and 
thus the expression level of late proteins which depend upon DNA replication could be 
affected. As to be expected from an inhibitory effect on a very specific step in 
morphogenesis, the extent of the 30E07 induced reduction of the viral protein expression 
was mild in comparison with the magnitude of the strong plaque reduction induced by the 
treatment. 
 
 
4.4.3.4 30E07 inhibits viral DNA replication 
The moderate reduction of viral protein levels by 30E07 treatment (4.4.3.3) could indicate an 
effect on DNA synthesis. To test this, the kinetics of viral DNA accumulation after infection 
was monitored in the presence of 30E07 and compared to samples which were treated with 
a specific polymerase inhibitor Foscarnet (PAA) or left untreated. Thus, HFF cells were 
infected with TB40-BAC4 at an MOI of 0.2 and overlaid with medium containing 1% DMSO, 
PAA (300 µg/ml) or 30E07 (100 µM), respectively. Total DNA was extracted from infected 
cells at different time points between 6 to 96 h after infection and the copy number of viral 
DNA was quantified using real-time PCR (3.3.11).  
Figure 29: Effect of 30E07 on viral protein 
expression levels. HFF were infected with 
TB40-BAC4 at an MOI of 0.2 pfu/cell. The 
infection was allowed to proceed in absence (-) 
and presence (+) of 30E07 (100 µM). At 
different time points cells were harvested and 
processed for Western blotting. Representative 
HCMV IE, E or L proteins (right) were 
visualized using respective antibodies. Cellular 
β-actin served as a loading control. Numbers 
on the left indicate the protein marker in kDa. 
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Table 2: Synthesis of HCMV-DNA in presence of PAA or 30E07. HCMV TB40-BAC4-infected cells 
were treated with DMSO, Foscarnet (PAA), or 30E07. Total intracellular DNA was harvested during a 
period of 96 h postinfection as indicated, and viral progeny DNA was measured by quantitative real-
time PCR (see methods 3.3.11). Values indicate UL54 gene copy numbers in relation to the cellular 
gene GAPDH copy numbers that served as standard. 
 
As control, the viral DNA polymerase inhibitor PAA exerted, as expected, a strong inhibitory 
effect on the accumulation of viral DNA between 48-96 h post infection (Table 2). Cells 
treated with 30E07 showed a less but still quite impressive inhibition of viral DNA synthesis. 
Thus, the 30E07 induced inhibition of viral protein expression is explained by the inhibitory 
effect on viral DNA replication. 
 
4.4.3.5 Analysis of ultrastructural phenotypes induced by 30E07 
30E07 affected HCMV DNA replication to some extent. However, this alone did not yet 
explain the complete inhibition of viral particle production at the effective concentration. To 
analyze the effect of 30E07 on viral morphogenesis, late-stage TB40-BAC4-infected HFF 
grown in absence and presence of 30E07 by electron microscopy were analyzed. To reduce 
the effect of 30E07 on DNA replication (see 4.4.3.4) and to make later steps of 
morphogenesis visible, the drug was added 3 days post infection, at a stage at or beyond the 
start of viral DNA synthesis. 
 
4.4.3.5.1 30E07 increases number of A-capsids in the nucleus 
HFF cells were infected at an MOI 1 with TB40-BAC4 and incubated for 3 days. Then the 
medium was exchanged to 30E07-containing medium (conc. 100 µM) or medium containing 
1% DMSO (control, no drug). Infected cells were further incubated for 2 days and then fixed 
and prepared for EM (3.9).  
To examine 30E07-induced effects on virus capsid maturation and fate, cell nuclei were 
analyzed for appearing capsid types. As expected, empty A, proteolytically cleaved B-, and 
DNA-filled C-capsids were readily detected in cells without drug-treatment (Figure 30 and 
Table 3; for further information (Yu et al., 2005)). In 30E07 treated cells, the number of C-
capsids was markedly reduced, while the contingent of A-capsids increased (Figure 30 and 
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Table 3). The percentage of B-capsids remained constant, indicating a non-disturbed 
scaffold maturation. Altogether, the proportional increase of A-capsids indicated a defect 
before or during the cleavage/packaging process (Yu et al., 2005). 
 
Figure 30: Ultrastructural analysis of effect of 30E07 on nulcear capsid formation. Transmission 
electron micro-graphs of ultrathin section preparations of TB40-BAC4-infected HFF cells. Medium 
containing DMSO (no drug) or drug (30E07, 100 µM) was applied 3 days post infection. Cells were 
fixed 5 days post infection and prepared for electron microscopic analysis. Representative images 
from the nucleus are shown for both treatments. Arrows indicate A-, B- and C-capsids, respectively. 
Scale bars: 500 nm. 
 
               
Table 3: Effect of 30E07 on HCMV capsid formation. 
4.4.3.5.2 The effect 30E07 on nuclear egress cannot be shown in the viral context 
Specific inhibitors of the NEC formation by interfering with the interaction of pUL50/pUL53 or 
their homologs should mainly provoke a reduced or blocked nuclear particle egress in alpha 
herpesviruses. A combined effect on DNA cleavage/packaging and on nuclear egress was 
expected in beta herpesviruses. Therefore the frequency of cytosolic capsids and the ratio 
between the nuclear and cytosolic capsids were analyzed. Viral assembly complexes in the 
cytoplasm could be found in treated and untreated cells (Figure 31) indicating that the 
cytoplasmic maturation machinery (Sanchez et al., 2000) is formed in the presence of the 
drug.  
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Figure 31: 30E07 does not affect generation of viral assembly compartment in the cytoplasma. 
Representative electron microscopic images of cytoplasms of DMSO-treated (no drug) and drug-
treated (+30E07) TB40-BAC4-infected HFF cells. Continous lines indicate the nucleus, dashed lines 
the viral assembly compartment. Scale bars: 5 µM. 
 
With respect to total numbers the amount of cytoplasmic capsids was strongly reduced in the 
presence of 30E07 compared to the untreated HCMV infected cells. The ratio between C-
capsids appearing in the cytoplasm (CyC) and C-capsids in the nucleus (NuC) in DMSO and 
drug-treated cells was quantified from the electron micrographs (Table 4). There was a clear 
reduction of the total number of capsids in nucleus and cytoplasm. Notably, there was no 
difference between the treated and untreated cells with respect to the ratio of nuclear and 
cytosolic capsids. At first sight, these data did not support the notion that 30E07 inhibited 
export of nuclear capsids. Yet, given that 30E07 was added as late as 3 days post infection, 
it could not be excluded that these few cytoplasmic capsids may represent stages of 
morphogenesis prior to the addition of the drug.  
 Results 
 
 80
 
 
Table 4: Ultrastructural analysis of effect of 30E07 on egress of nucleocapsids. Quantification of 
nuclear and cytoplasmic C-capsids in drug treated and untreated HFF cells 5 days post infection. 4 
cells were analyzed for each treatment.  
 
4.4.3.5.3 30E07 does not affect secondary envelopment 
To investigate potential effects of 30E07 on morphogenesis steps further downstream in the 
viral replication cycle, the cytoplasm of infected cells untreated and treated with 30E07 were 
analyzed for cytoplasmic capsid envelopment (Figure 32). The overall number of C-capsids 
in the cytoplasm was low compared to mock-treated infected cells (also see 4.4.3.5.2). Yet, 
C-capids which could be found in the cytoplasm of drug-treated cells were regularly 
enveloped like in non-treated cells, excluding that 30E07 affected the secondary capsid 
envelopment step. 
 
Figure 32: Ultrastructural analysis of effect of 30E07 on cytoplasmic capsid envelopment. 
Representative electron microscopic images of cytoplasms of DMSO-treated (no drug) and drug-
treated (+30E07) TB40-BAC4-infected HFF cells. Arrows indicate secondary enveloped C-capsids. 
Scale bars: 500 nm. 
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5. Discussion 
Human Cytomegalovirus (HCMV) is an opportunistic pathogen leading to severe morbidity 
and mortality in immunocompromised patients and represents the major viral cause of birth 
defects (Britt, 1999). Currently, the most effective way to control CMV infection, given the 
lack of an effective vaccine, is by antiviral chemotherapy. Almost all anti-HCMV drugs on the 
market to date are nucleoside analogues inhibiting the viral DNA polymerase. Although these 
drugs have proved to be successful in management of HCMV disease they suffer from 
bioavailability and long-term toxicity problems and the development of resistant strains. The 
similar mode of action in targeting the same protein in the viral machinery implicates 
furthermore an increased risk of cross-resistance. Therefore, there is an urgent need for new 
antivirals with different target structure. 
 
In this work there was a focus on small molecular inhibitors in their ability to block essential 
viral protein-protein interactions governing primary envelopment of intranuclear viral capsids 
at the nuclear membrane and governing secondary envelopment of cytoplasmic viral capsids 
in the cytoplasmic virus factories. A HTS platform was set up testing the core interaction of 
the HCMV NEC. In a second line of this work, a PCA based set-up was established enabling 
future inhibitory screens for cytoplasmatic envelopment. 4,000 compounds from a library of 
highly diverse heterocyclic structures (Bauer et al., 2011) were screened by this novel, cell-
free approach of target specific protein fragment complementation assay (PCA). Candidate 
compounds from the screen were further characterized for their mode of action and antiviral 
effects.  
 
5.1 PCAs as HTS screening tool for inhibitors of protein-protein interactions 
In a PCA, two fragments of a reporter enzyme are fused to the proteins of interest. The 
individual fragments are non-functional; however, interaction of the two proteins brings them 
into proximity allowing correct folding and reconstitution of functional activity of the reporter. 
Described PCA applications were performed in vivo, in the context of living cells (Michnick et 
al., 2007). In this setting, proteins can be studied in their natural context, ensuring sub-
cellular targeting, post-translational modifications and interactions with other proteins 
required for folding. Therefore, PCAs were proposed as HTS screening tool for interacting 
proteins and inhibitors in cell-based assays. Remy and Michnick (Remy and Michnick, 2004) 
reported about a GFP-PCA based functional cDNA library screen for interaction partners of 
the protein kinase PKB/Akt. In our lab, such a cell-based PCA was previously used to 
characterize the core interaction within of the UL31/UL34 family which allowed comparative 
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studies addressing a comprehensive set of NEC homologs representing all herpesvirus 
subfamilies (Schnee et al., 2006). However, cell-based assays are not optimal for high-
throughput screening approaches for inhibitors. Cell-based assays are complex, either due to 
the high costs and the preclusion of cytotoxic compounds leading to a lack of information 
about inhibiting structures in toxic compounds.  
 
In this study, the recently developed cell-free setting based on a β-lactamase (Bla)-PCA was 
used in which the protein-protein interaction can be studied in isolation (Schnee et al., 2012). 
PCAs based on Bla are dynamic and reversible, other than those using for example 
fluorescent reporter proteins like GFP and YFP (Magliery et al., 2005; Nyfeler et al., 2005). 
They enable to detect interactions in real-time using kinetic detection modes. As an example 
we have chosen the core interaction of the HCMV-NEC formed by pUL50 and pUL53. It was 
shown that this protein interaction is essential for viral growth (Bubeck et al., 2004). The 
interaction of both proteins and their homologs in other herpesviruses were studied by our 
group and others (Bubeck et al., 2004; Lotzerich, Ruzsics, and Koszinowski, 2006; Sam et 
al., 2009). The interaction is non-obligatory (De et al., 2005) and direct (Sam et al., 2009). 
The interactions sites on both proteins were shown to be small and linear and single point 
mutations in the binding motifs affected or completely abolished the binding (Bubeck et al., 
2004; Lotzerich, Ruzsics, and Koszinowski, 2006; Sam et al., 2009). Therefore, it was 
assumed that a small molecule might inhibit this interaction. Last but not least, as there was 
no information concerning 3D structures of the proteins allowing a structure-based drug 
design, a high-throughput screening (HTS) approach was used in this work to identify 
inhibitors of this interaction. 
 
Therefore, PCA was suitable as a cost effective approach for high-throughput screening 
(HTS) for small inhibitory compounds of the pUL50/pUL53 interaction. 
 
 
5.2 Standardization of the in vitro NEC-PCA (iPCA)  
In this work, the iPCA made use of a chemical compound library to identify inhibitors of the 
pUL50/pUL53 interaction. First of all, the assay was adapted to high-throughput format. 
During this process, the minimal amounts of proteins were determined necessary in the 
assay to give a specific signal. The protein concentration was standardized and minimized to 
enlarge the number of possible screens which could be performed with one protein 
purification. At present it is possible to perform more than 400 single assays with purified 
protein from one 2.5 l bacterial culture. Furthermore, the iPCA was tested for DMSO 
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tolerance and the readout was changed from real-time to an endpoint measurement by 
introduction of a stop solution. Compared to the in vitro PCA described by Hahimoto and 
colleagues using mKG fused target proteins (Hashimoto et al., 2009) in which the screening 
reaction altogether takes 18 h, the total reaction time of the iPCA could be limited to 40 min, 
a substantial time saving of this assay. Although the PCA in the context of in vitro translation 
is advanced compared to cell-based systems regarding the compartmentalization issues, it 
suffers from high costs and low yields with respect to protein production. 
A counter-screen was developed for excluding compounds having a direct effect on the 
reporter enzyme β-lactamase. This was necessary because our system utilized a single 
reporter reaction as readout. Thus, the risk for false positive results could be filtered out. This 
increase in specificity is demonstrated by the results. 
 
5.3 Towards an inhibitor of the secondary envelopment of HCMV 
In the second part of this work, a further essential viral protein-protein was transferred into 
the iPCA system and a set-up should be established which can be used in future high-
throughput inhibitor screens. The interaction built up by the HCMV proteins pUL94 and 
pUL99 (To et al., 2011) termed here as the secondary envelopment complex (SEC) seemed 
to be an attractive and suitable platform.  
 
The interaction occurs at late times in infection, when infectious progeny are being produced 
(Phillips and Bresnahan, 2011a). pUL99 localizes to the viral assembly complex and is 
essential for secondary envelopment of virions in the cytoplasm (Seo and Britt, 2007; Silva et 
al., 2003). In the absence of pUL99, partially tegumented but non-enveloped capsids 
accumulate in the cytoplasm, and no infectious virus is released. Localization of pUL99 to the 
cytoplasmic assembly complex is essential for virus replication (Seo and Britt, 2006; Seo and 
Britt, 2007). In this context, pUL94 is suggested to have an essential function in directing 
pUL99 to the assembly complex, thereby facilitating secondary envelopment of virions 
(Phillips and Bresnahan, 2011a). The amino acid residues of pUL99 essential for binding to 
pUL94 are located in a small linear motif (Liu et al., 2009) in the N-terminal half of the 
protein, while less information is available about pUL94. Binding site analysis by larger 
deletion mutants always resulted in a complete loss of interaction suggesting a non-linear 
binding motif and advanced structure required for interaction (Liu et al., 2009). However, 
recently it was shown that a point mutation in aa 343 in the very C-terminus of the protein 
disrupts co-localization to pUL99 (Liu et al., 2012). Furthermore, for its MCMV homolog 
pM94 a 5 aa-insertion mutant in the N-terminus was identified failing to interact with pM99, 
the homolog of pUL99 (Maninger et al., 2011). The strong effect of these subtle mutations 
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and the small linear binding motif in pUL99 indicate a limited interface of the pUL94/pUL99 
interaction, pointing out the possibility that a small inhibitor might be able to block the SEC 
formation or stability. 
 
To determine if the pUL94/pUL99 can be monitored by PCA, the interaction was tested in 
cell-based PCA. Because our lab previously studied extensively on the genetics of the 
MCMV homolog pM94 (Maninger et al., 2011) and thereby binding deficient mutants to pM99 
were already at hand, the study first started on the interaction of the MCMV proteins. To this 
aim, new Gateway®-based plasmids were created which allow an easy and fast of tagging 
proteins with the Bla-fragments at the N-terminus. Besides of tagging pM94 and pM99 and 
the non-binding mutant of pM94 with a 5 aa insertion at position 13 (Maninger et al., 2011), 
Bla-tagged variants of pM50 and pM53 and the non-binding version of pM50 (Bubeck et al., 
2004) were also created. The interaction of pM53 and pM50 was previously shown to be 
suitable in PCA (Schnee et al., 2006) and should serve here as a control for the Gateway®-
tagging approach. The signal to background ratio of the pM50/pM53 interaction monitored by 
the Bla-tagged constructs derived from Gateway® plasmids was with factor of around 15 
comparable to that described by Schnee et al. (Schnee et al., 2006). Consequently, the new 
cloning platform did not hamper the NEC proteins to interact properly. When N-M94 and C-
M99 were co-expressed, the hydrolysis rate of nitrocefin in the cell lysates resulted in 20 fold 
higher hydrolysis rate than the hydrolysis rates derived from co-expression of N-M94i13 and 
C-M99 or any single expression of these proteins, respectively. Furthermore, the signal 
specificity could be confirmed in a competition experiment by co-expression with untagged 
pM99. These experiments led to two conclusions. First, the successful Bla-tagging via the 
Gateway® approach allows a fast and easy way of cloning for future studies on viral protein 
interactions by PCA. Second, the interaction of pM94 and pM99 can be monitored by cell-
based PCA. The studies of Maninger et al. created a set of insertion mutants of pM94 with 
unknown molecular phenotype which were not able to complement in the pM94-deletion 
background. The insertion mutants can now be categorised in an easy way by testing them 
in the established pM94/pM99 PCA for their ability in binding pM99. Non-viable mutants still 
able to bind pM99 would further support the thesis of a second unknown function of the 
protein (Maninger et al., 2011). 
 
Because the previous studies on the MCMV homologs showed tagging with the Bla-
fragments without any sterical constraints, there was an indication that the interaction of the 
HCMV homologs pUL94 and pUL99 might also be monitored by PCA when proteins were 
Bla-tagged in a similar way. As control for background a deletion mutant of pUL99 was BlaC-
tagged (CUL99del) lacking the responsible residues for binding to pUL94 as predicted by Liu 
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and colleagues (Liu et al., 2009). Co-expression of NUL94 and CUL99 resulted in a more 
than 90 times higher nitrocefin hydrolysis rate than in single expression lysates of the tagged 
constructs showing a specific reconstitution of Bla activity upon co-transfection.  
 
With a working cell-based PCA for the MCMV and HCMV SEC proteins in hands, the 
conserved properties of the proteins between the different β-herpesviruses should be 
underlined. The consensus sequence between pUL94 and pM94 accounts for 48%. 
Therefore it was likely that motifs which are responsible for binding pUL99/pM99 might be 
conserved between species. This would expand the impact of a potential inhibitor on the 
HCMV SEC interaction also to MCMV. To analyze this, the Bla-tagged constructs were used 
in a cross-complementation assay similar to that described for pM50/pM53 interaction 
described by Schnee and colleagues (Schnee et al., 2006). Thereby, the N-M94 was also 
able to complement with CUL99, while the N-M94i13 and CUL99del did not. Future studies 
including the homologous proteins of alpha and gamma herpesviruses in the cell-based PCA 
might further elucidate the common and specific properties of the UL16 and UL11 protein 
families. 
 
However, the final interest in the framework of this study was to transfer the interaction to the 
PCA format in that way that it is possible to screen for inhibitory compounds in larger scale. 
For this purpose, it was of great benefit that the fusion proteins could interact in the assay 
when they were produced isolated from each other (Figure 18) indicating that the interaction 
of pUL94 and pUL99 is non-obligatory. 
 
Next, it was of interest if it was possible to produce one or both fusion proteins in bacteria to 
further enable a scale-up of the assay. The bacterial derived BlaC-tagged pUL99 could 
replace the eukaryotic-derived fusion protein. However, the BlaN-tagged pUL94 did not 
complement with BlaC-tagged pUL99 versions. This might be due to instabilities caused by 
protein degradation. Liu and colleagues showed that already minor truncations in pUL94 (Liu 
et al., 2009) always resulted in a total loss of binding properties to pUL99. Accordingly, 
Western blot analysis of the bacterial derived construct (Figure 20B) lacked a distinct band 
for NUL94-His and showed a protein pattern indicating degradation. Failures in post-
translational protein modification caused by prokaryotic expression or chaperon dependant 
folding of the protein may also contribute.  
 
Escherichia coli-based cell-free systems are described to underperform in folding of 
multidomain proteins in comparison to eukaryotic systems (Hirano et al., 2006; Langlais et 
al., 2007; Zarate et al., 2010). For future larger screens the change to a eukaryotic 
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expression of pUL94 may be considered. Besides the traditional yeast and baculovirus 
systems, Kovtun and colleagues recently described a cell-free protein expression system 
derived from Leishmania enabling the production of eukaryotic proteins in large scale in a 
rapid and cost-effective way (Kovtun et al., 2011).  
 
Nevertheless, the present system is already suitable for screens with pUL99 (pUL94) derived 
peptides to further characterize the interaction. Thereby, short peptides mimicking stretches 
of pUL99 especially in the linear binding region to pUL94 (Liu et al., 2009) appear promising. 
 
5.4 The in vitro NEC-PCA (iPCA) in the high-throughput inhibitor screen 
A compound library of 4,000 structurally highly diverse potentially non-toxic compounds with 
pharmacological properties which were selected from a small-molecule library containing 
30,000 individual heterocyclic structures (EMC microcollections, Tübingen) was screened 
with the standardized iPCA. This library has been already tested for toxicity in different 
mammalian cell lines (Caco-2, HeLa, A549 and A431) (Bauer et al., 2011) and was provided 
by EMC microcollections (Tübingen). The iPCA would also enable to screen highly cytotoxic 
compounds, however, this selection allowed a further characterization of the hits in the viral 
context. 
Of almost 100 candidates only 2 were identified showing inhibition in the iPCA but not 
affecting the β-lactamase in the counter-screen. Both compounds, termed here 30E06 and 
30E07, were structurally related suggesting a common mechanism of action.  
To further test target specificity, the compounds were tested on primary and continuous cell 
lines for general cytotoxic effects. 30E07 showed less toxicity than 30E06 and was therefore 
used for further cell-based assays for the pUL50/pUL53 interaction. 30E07 significantly 
reduced the nitrocefin hydrolysis rate when applied in the cell-based NEC-PCA (Figure 25) 
which was established previously in our lab to monitor pUL50/pUL53 interaction in real-time 
(Schnee et al., 2006). Furthermore, immunofluorescence studies demonstrated that pUL53 
delocalizes from the nuclear rim in presence of pUL50 upon drug treatment. The pUL53 was 
distributed homogenously all over the nucleus like it was described previously for pUL53 in 
single transfection experiments (Dal Monte et al., 2002; Muranyi et al., 2002). Both findings 
indicated a direct influence of 30E07 on pUL50/pUL53 interaction. Therefore, the two 
identified hits acted target specific in vitro and in cells.  
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5.4 Characterization of the antiviral effect of the NEC inhibitors 
As a specific inhibition of the NEC formation by of the identified compounds was observed, 
both candidates were tested for their antiviral activity against HCMV. Interestingly, 30E06 
and 30E07 showed a dose-dependant antiviral effect on HCMV when applied in non-toxic 
concentrations. To elucidate the on target and off target modes of action, the effect of 30E07 
on viral gene expression was tested. Thereby, a certain reduction in viral protein expression 
levels was observed for HCMV infected cells treated with the compound in the highest non-
toxic dose. This observation stood in contrast to our expectation that viral protein expression 
should not be harmed by the drug when affecting the pUL50/pUL53 interaction which acts 
further downstream in the viral replication cycle. For example, the anti-cytomegalovirus 
compound AIC246 which acts selectively on capsid packaging and egress and therefore 
further downstream was described to show no influence on immediate, early and late protein 
expression levels (Goldner et al., 2011). Deficiency in viral protein expression levels could 
result from reduced viral DNA replication in herpesviruses. For that reason, an upstream 
effect of 30E07 on viral DNA synthesis was assumed. To clarify this, 30E07 was tested by 
quantitative real-time PCR (qPCR) for effects on HCMV genome copy numbers during the 
first viral replication cycle. A marked inhibition on the de novo synthesis of progeny DNA was 
observed in 30E07 treated infected cells confirming the upstream effect thesis. To elucidate, 
if the compound also affects other steps in viral morphogenesis late-stage HCMV-infected 
cells were analyzed in absence and presence of the compound by electron microscopy. The 
decision which capsid type is formed from the circular pro-capsid depends on the timing of 
scaffold protein cleavage and recruitment of unit-length viral DNA (Yu et al., 2005). An 
Increase of either A- or/and B-capsids, which are believed to be non-functional dead-end 
products, reflects an interference with the process of capsid maturation. Increased numbers 
of B-capsids are often observed in infected cells treated with drugs targeting the capsid 
packaging process itself like for the anti-cytomegalovirus compounds AIC246 and 
benzimidazole-D-ribonucleosides, which were shown to target the viral terminase or the 
portal protein (Dittmer et al., 2005; Goldner et al., 2011; Krosky et al., 1998). In the case of 
30E07 no change in B-capsid number could be observed and therefore it is unlikely that 
30E07 affected the capsid packaging process. 
However, there was a remarkable increased number of empty A-capsids in the nucleus of 
drug-treated cells while the number of DNA-filled C-capsids decreased. A-capsids result from 
a premature cleavage of the scaffold protein before DNA is incorporated into the capsid. 
Although the drug was applied later in infection (day three post infection), the increased 
number of A-capsids in drug-treated cells might resulted from the delay in viral DNA 
synthesis provoked by the drug from the moment of application. 
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Because the compounds originated from the screen for inhibitors of the pUL50/pUL53 
interaction, which is essential in the process of nuclear capsid egress, it was of interest if an 
effect on nuclear egress could be observed for 30E07. Cytoplasmic capsids and a regular 
assembly complex could still be found in drug-treated cells, which excluded a complete block 
of egress. To evaluate if the egress process was anyhow disturbed by the drug, the number 
of C-capsids appearing in the cytoplasm in relation to C-capsids from the nucleus from 
untreated and drug-treated cells was quantified. However in both cases, the percentage of 
cytoplamic C-capsids was around 9%. Furthermore, the cytoplasmic capsids showed regular 
secondary envelopment, which led to the conclusion that processes downstream of viral 
DNA synthesis are not harmed by the drug. However, due to the significant decrease of the 
C-capsids in the drug treated cells and low overall number cytosolic capsids this later 
findings are only indicative. A final conclusion to this regard requires further studies. 
 
5.4.1 Targeted effect of the screening hits on NEC functions 
In summary, we could show that we were able to identify small inhibitory compounds 
targeting the pUL50/pUL53 interaction of HCMV in vitro. The candidate 30E07 from the HTS 
also showed inhibition on pUL50/pUL53 interaction in cell-based assays. We could clearly 
show that in co-transfection experiments pUL53 is diffusing homogenously in the nucleus 
and is not targeted to the nuclear rim to pUL50 in presence of the drug (Figure 26). This 
strongly argues for a targeted effect of the drugs. Next it should be perhaps tested whether 
pUL53 is also dissociated in drug-treated cells during infection in the complete viral context. 
Furthermore, both identified candidates from the HTS (30E07 and 30E06) exhibited an 
antiviral effect on HCMV accompanied by an impaired viral protein and DNA synthesis and 
an inhibition of nuclear capsid maturation. Yet, we could not find any direct evidence that 
30E07 inhibits nuclear capsid egress in the viral context.  
 
Do the observed drug effects reflect selectively properties of the targets or do they represent 
also off target effects? Most of what is currently known about the pUL34/pUL31 of β-
herpesviruses originates from studies on dominant-negative (DN) mutants (for more 
information see (Veitia, 2007)) of both proteins. DNs of pM50 (pUL34 family of MCMV) solely 
showed a defect in nuclear egress (Bubeck et al., 2004), while pM53 (pUL31 family of 
MCMV) DNs showed an additional effect on DNA cleavage/DNA capsid packaging and 
maturation (Popa et al, 2010; Pogoda et al., 2012 in revision). Furthermore, a significant 
increase of A-capsids reflected an additional effect of pM53 on viral DNA replication which 
could recently be verified by qPCR studies (Madlen Pogoda, personal communication). 
Similarly, in α-herpesviruses, knock-out mutants of pUL31 of HSV-1 showed, besides a 
defect in nuclear egress, a negative effect on synthesis and packaging of viral DNA (Chang 
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et al., 2012) and also a delayed expression of viral gene products (Roberts and Baines, 
2011). The latter phenotypes were exclusively observed for pUL31- but not for pUL34-null 
mutants. Studies with knock-out and charge cluster mutations of pUL34 ascribed to the 
protein a role in proper primary envelopment and lamina alteration as well as a recruitment 
function of appropriate components to nucleocapsid budding sites (Roller et al., 2010; Wills, 
Mou, and Baines, 2009). Furthermore, the MCMV homolog pM50 appeared to be crucial to 
prevent a late stress response by the host cell (Stahl, S. 2012, "Modulation of the Unfolded 
Protein Response by Murine Cytomegalovirus", 22nd Annual Meeting of the Society for 
Virology, Essen (Germany), p. 360) which might lead to disturbance of the late protein 
synthesis. 
 
Studies on γ-herpesvirus homologs in EBV showed only partial overlapping phenotypes 
compared to the α- and β-homologs described above. Both protein deletion viruses showed 
the expected alteration in primary egress. However, the observed abnormal capsid 
maturation for the pUL31 homolog (BFLF2)-null mutant could not be ascribed to impaired 
viral DNA synthesis or monomeric genome production (Farina et al., 2005; Granato et al., 
2008). 
Taking these studies on α- and β-herpesvirus homologs into account gives evidence that the 
lead compounds generate effects that can be explained by the action on pUL50 and pUL53.  
The failure to observe direct effects on nuclear capsid egress might be a result of the 
experimental set-up in the EM study. We could hardly find any capsid at all when we applied 
the drug on the day of infection (data not shown). Therefore, to permit some quantification 
we delayed the drug application to d3 post infection. It has to be assumed that prior to the 
onset of drug function there were already some C-capsids showing up all known stages, 
including cytosolic stages. The observed C-capsids in the cytosol at day 5 post infection in 
drug-treated cells may represent these capsids. The fact that the absolute numbers of C-
capsids observed in the cytosol in presence of the drug were very low compared to the 
wildtype case (see Table 4) supports this notion. We do not know fate and half life of newly 
synthesized nuclear capsids, which are mainly dead-end products (A- and B-capsids) in 
drug-treated cells. If we expect a shorter half-life for the dead-end products in the nucleus, 
this would reduce the overall numbers of the capsids in drug treated cells and would 
therefore also decrease the ratio of the capsids in- and outside of the nucleus. Future EM 
studies on the kinetics of morphogenesis could elucidate these questions. 
 
A further aspect we have to consider is that also another protein-protein interaction is 
blocked by the drugs. Studies on pM53 (Pogoda et al., 2012, in revision) suggest 
homodimerization of this protein which is abolished in DN mutants of pM53. If the drug 
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provokes monomeric pUL53 to take a conformation, which is functionally comparable to the 
DN-properties of the protein mutants (Popa et al. 2010; Pogoda et al., 2012, in revision) 
phenotypes must occur that go beyond the lack of pUL50 and pUL53 interaction. Such 
phenotypes may occur at earlier stages of capsid morphogenesis. Studies on pUL53 and 
pUL50-null mutants have not yet been carried out and would certainly help to complete the 
picture about the functions of the two proteins in β-herpesviruses. 
Future drug studies will have to be performed to specify these effects of 30E07. However, it 
is might be advantageous to wait with such extensive experimental settings until the lead 
structure is optimized. Besides the above mentioned studies, ligand binding assays could 
ascertain a potential interaction (reviewed in (de Jong et al., 2005; Sittampalam, Kahl, and 
Janzen, 1997)). 
 
5.4.2 Perspectives of the screening hits 
Perfect drugs do not emerge from early screens. The identified candidates are leads, which 
need to be optimized in further studies to get to the point of clinical relevance. Therefore, 
structure activity relationship (SAR) studies are needed to improve relevant features of the 
lead compounds. In our special case this would start from the stereospecific synthesis of the 
compounds 30E07 and 30E06. Both compounds exhibit the same core structure (Figure 
23A) holding 3 stereocentres equivalent to 8 possible stereoisomers. The percentage of each 
stereoisomer in the compound solution used in the screen was not known though 30E06 and 
30E07 were synthesized an achiral manner. Therefore, each stereoisomer will have to be 
produced in an isolated form and retested in the iPCA and cell-based assays for the 
identification of the active stereoisomer. Further compound modifications will be needed that 
reduce cellular toxicity and increase target selectivity. X-ray crystallographic studies on the 
pUL50 and pUL53 proteins would provide useful information for enhanced inhibitor activity. 
So far, crystallization attempts on these proteins and homologs were not successful due to 
low solubility of the full-length proteins (Gonnella et al., 2005; Lake and Hutt-Fletcher, 2004). 
However, Sam and colleagues recently described the production of stable, truncated forms 
of pUL50 and pUL53 (Sam et al., 2009) still able to interact, which might serve as attractive 
platform for new efforts. 
 
Altogether, this proof of concept study demonstrated that small-molecule inhibitors can be 
identified by cell-free NEC-PCA, which can become a useful basis for anti-cytomegalovirus 
drug development. We believe that future screenings in more extended compound libraries, 
combined with structure-activity studies will provide an effective small-molecule inhibitor for 
the interaction of pUL50/pUL53 which would allow to go forward to in vitro and in vivo testing 
for activity in CMV disease. 
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5.5 Concluding remarks  
The data presented here show that the β-lactamase based in vitro PCA (Schnee et al., 2012) 
is suitable to be applied in a high-throughput screen for small molecule inhibitors of protein-
protein interactions. Furthermore, it was demonstrated that the system is transferable to 
other protein interactions. 
Most importantly, this work proves for the first time that a small molecule is able to inhibit the 
interaction of pUL50/pUL53. This confirms the assumption of a limited binding site and the 
suitability of this protein-protein interaction as a potential drug target. 
Taken together, this work provides new insights and tools in screening for inhibitors of 
essential viral protein-protein interactions on the way to new antivirals against HCMV with 
unique mode of action. 
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7.3 Abbreviations 
aa  amino acid 
AIDS  acquired immunodeficiency syndrome 
APS  ammonium persulfate 
BAC  bacterial artificial chromosome 
BiFC  bimolecular fluorescence complementation 
Bla  TEM-1 β-lactamase 
bp  base-pair 
BSA  bovine serum albumin 
dpi  days post infection 
DMEM  Dulbecco's modified eagle's medium 
DMSO  dimethylsulfoxid 
dNTP  desoxyribonuleotide  
E  early 
e  elutions 
EM  electron microscopy 
FCS  fetal calf serum 
FOM  fomivirsen 
GCV  ganciclovir 
HA  hemagglutinin 
HCMV  human cytomegalovirus 
HFF  human foreskin fibroblasts 
HRP  horseradish peroxidase 
HSV  herpes simplex virus 
HTS  high-throughput screening 
IC  inhibitory concentration 
IE  immediate-early 
IF  immunofluorescence 
IPTG  isopropyl-ß-D-thiogalactopyranosid 
iPCA  in vitro NEC-PCA 
kbp  kilo base-pair 
kDa  kilo daltons 
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L  late 
luc  luciferase 
MCMV  murine cytomegalovirus 
MEF  mouse embryonic fibroblasts 
MOI  multiplicity of infection 
MW  molecular weight 
NEC  nuclear egress complex 
ORF  open reading frame 
PAA  phosphonoacetic acid 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PCA  protein fragment complementation assay 
PCR  polymerase chain reaction 
pfu  plaque-forming unit 
qPCR  quantitative real-time PCR 
RT  room temperature 
SARS  severe acute respiratory syndrome 
SDS  sodium dodecyl sulfate 
SEC  secondary envelopment complex 
TBS-T  TRIS-buffered saline withTween-20 
TD-PCR Touchdown PCR 
TEMED N,N,N′,N′-Tetramethylethan-1,2-diamin 
w/v  weight per volume 
Y2H  yeast two-hybrid
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